The present invention relates to methods and apparatus for neuromodulation. More particularly, the present invention relates to methods and apparatus for achieving renal neuromodulation via thermal heating and/or cooling mechanisms.
Congestive Heart Failure (“CHF”) is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes altered, which results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidneys and circulatory system.
It is believed that progressively decreasing perfusion of the kidneys is a principal non-cardiac cause perpetuating the downward spiral of CHF. Moreover, the fluid overload and associated clinical symptoms resulting from these physiologic changes result in additional hospital admissions, poor quality of life and additional costs to the health care system.
In addition to their role in the progression of CHF, the kidneys play a significant role in the progression of Chronic Renal Failure (“CRF”), End-Stage Renal Disease (“ESRD”), hypertension (pathologically high blood pressure) and other cardio-renal diseases. The functions of the kidneys can be summarized under three broad categories: filtering blood and excreting waste products generated by the body's metabolism; regulating salt, water, electrolyte and acid-base balance; and secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of waste toxins in the blood and body. These conditions result from reduced renal function or renal failure (kidney failure) and are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as fluids are retained and blood toxins accumulate due to the poorly functioning kidneys.
It has been established in animal models that the heart failure condition results in abnormally high sympathetic activation of the kidneys. An increase in renal sympathetic nerve activity leads to decreased removal of water and sodium from the body, as well as increased renin secretion. Increased renin secretion leads to vasoconstriction of blood vessels supplying the kidneys, which causes decreased renal blood flow. Reduction of sympathetic renal nerve activity, e.g., via denervation, may reverse these processes.
Applicants have previously described methods and apparatus for treating renal disorders by applying a pulsed electric field to neural fibers that contribute to renal function. See, for example, Applicants' U.S. Pat. Nos. 7,653,438, 8,145,316, and 7,620,451, all of which are incorporated herein by reference in their entireties. A pulsed electric field (“PEF”) may initiate renal neuromodulation, e.g., denervation, for example, via irreversible electroporation or via electrofusion. The PEF may be delivered from apparatus positioned intravascularly, extravascularly, intra-to-extravascularly or a combination thereof. Additional methods and apparatus for achieving renal neuromodulation, e.g., via localized drug delivery (such as by a drug pump or infusion catheter) or via use of a stimulation electric field, etc, are described, for example, in Applicants' U.S. Pat. Nos. 7,162,303 and 6,978,174, both of which are incorporated herein by reference in their entireties.
A potential challenge of using PEF systems for treating renal disorders is to selectively electroporate target cells without affecting other cells. For example, it may be desirable to irreversibly electroporate renal nerve cells that travel along or in proximity to renal vasculature, but it may not be desirable to damage the smooth muscle cells of which the vasculature is composed. As a result, an overly aggressive course of PEF therapy may persistently injure the renal vasculature, but an overly conservative course of PEF therapy may not achieve the desired renal neuromodulation.
Applicants have previously described methods and apparatus for monitoring changes in tissue impedance or conductivity in order to determine the effects of pulsed electric field therapy, e.g., to determine an extent of electroporation and/or its degree of irreversibility. See, for example, Applicants' co-pending U.S. Patent Application Publication No. US 2007/0083239, which is incorporated herein by reference in its entirety. However, in some patients it may be difficult or impractical to achieve such real-time monitoring when utilizing pulsed electric field neuromodulatory mechanisms. In some patients, this may necessitate re-intervention should it be established after the procedure that a degree of induced neuromodulation was not sufficient to achieve a desired treatment outcome. Thus, it would be desirable to achieve renal neuromodulation via more easily monitored and/or controlled neuromodulatory mechanisms.
Several embodiments of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:
A. Overview
The present invention provides methods and apparatus for renal neuromodulation via thermal heating and/or thermal cooling mechanisms, e.g., to achieve a reduction in renal sympathetic nerve activity. Thermally-induced (via heating and/or cooling) neuromodulation may be achieved via apparatus positioned proximate target neural fibers, for example, positioned within renal vasculature (i.e., positioned intravascularly), positioned extravascularly, positioned intra-to-extravascularly or a combination thereof. Thermal neuromodulation by either heating or cooling may be due to direct effect to, or alteration of, the neural structures that is induced by the thermal stress. Additionally or alternatively, the thermal neuromodulation may at least in part be due to alteration of vascular structures, e.g., arteries, arterioles, capillaries or veins, which perfuse the target neural fibers or surrounding tissue. Furtherstill, the modulation may at least in part be due to electroporation of the target neural fibers or of surrounding tissue.
As used herein, thermal heating mechanisms for neuromodulation include both thermal ablation and non-ablative thermal injury or damage (e.g., via sustained heating or resistive heating). Thermal heating mechanisms may include raising the temperature of target neural fibers above a desired threshold, for example, above a body temperature of about 37° C., e.g., to achieve non-ablative thermal injury, or above a temperature of about 45° C. (e.g., above about 60° C.) to achieve ablative thermal injury.
As used herein, thermal cooling mechanisms for neuromodulation include non-freezing thermal slowing of nerve conduction and/or non-freezing thermal nerve injury, as well as freezing thermal nerve injury. Thermal cooling mechanisms may include reducing the temperature of target neural fibers below a desired threshold, for example, below the body temperature of about 37° C. (e.g., below about 20° C.) to achieve non-freezing thermal injury. Thermal cooling mechanisms also may include reducing the temperature of the target neural fibers below about 0° C., e.g., to achieve freezing thermal injury.
In addition to monitoring or controlling the temperature during thermal neuromodulation, a length of exposure to thermal stimuli may be specified to affect an extent or degree of efficacy of the thermal neuromodulation. The length of exposure to thermal stimuli is longer than instantaneous exposure, such as longer than about 30 seconds, or even longer than 2 minutes. Furthermore, the length of exposure can be less than 10 minutes, though this should in no way be construed as the upper limit of the exposure period. Exposure times measured in hours, days or longer, may be utilized to achieve desired thermal neuromodulation.
When conducting neuromodulation via thermal mechanisms, the temperature threshold discussed previously may be determined as a function of the duration of exposure to thermal stimuli. Additionally or alternatively, the length of exposure may be determined as a function of the desired temperature threshold. These and other parameters may be specified or calculated to achieve and control desired thermal neuromodulation.
In some embodiments, thermally-induced renal neuromodulation may be achieved via direct application of thermal cooling or heating energy to the target neural fibers. For example, a chilled or heated fluid can be applied at least proximate to the target neural fiber, or heated or cooled elements (e.g., a thermoelectric element or a resistive heating element) can be placed in the vicinity of the neural fibers. In other embodiments, thermally-induced renal neuromodulation may be achieved via indirect generation and/or application of the thermal energy to the target neural fibers, such as through application of a ‘thermal’ electric field, of high-intensity focused ultrasound, of laser irradiation, etc., to the target neural fibers. For example, thermally-induced renal neuromodulation may be achieved via delivery of a pulsed or continuous thermal electric field to the target neural fibers, the electric field being of sufficient magnitude and/or duration to thermally induce the neuromodulation in the target fibers (e.g., to heat or thermally ablate or necrose the fibers). Additional and alternative methods and apparatus may be utilized to achieve thermally-induced renal neuromodulation, as described hereinafter.
When utilizing thermal heating mechanisms for thermal neuromodulation, protective cooling elements, such as convective cooling elements, optionally may be utilized to protect smooth muscle cells or other non-target tissue from thermal damage during the thermally-induced renal neuromodulation. Likewise, when utilizing thermal cooling mechanisms, protective heating elements, such as convective heating elements, may be utilized to protect the non-target tissue. When thermal neuromodulation is achieved via thermal energy delivered intravascularly, the non-target tissue may be protected by utilizing blood flow as a conductive and/or convective heat sink that carries away excess thermal energy (hot or cold). For example, when blood flow is not blocked, the circulating blood may provide a relatively constant temperature medium for removing the excess thermal energy from the non-target tissue during the procedure. The non-target tissue additionally or alternatively may be protected by focusing the thermal heating or cooling energy on the target neural fibers such that an intensity of the thermal energy is insufficient to induce the thermal damage in the non-target tissue distant from the target neural fibers.
In some embodiments, methods and apparatus for real-time monitoring of an extent or degree of neuromodulation or denervation (e.g., an extent or degree of thermal damage) in the target neural fibers and/or of thermal damage in the non-target tissue may be provided. Likewise, real-time monitoring of the thermal energy delivery element may be provided. Such methods and apparatus may, for example, comprise a thermocouple or other temperature sensor for measuring the temperature of the monitored tissue or of the thermal energy delivery element. Power or total energy delivered additionally or alternatively may be monitored.
To better understand the structures of devices of the present invention and the methods of using such devices for thermally-induce renal neuromodulation, it is instructive to examine the renal anatomy in humans.
B. Renal Anatomy Summary
With reference to
C. Embodiments of Apparatus and Methods for Neuromodulation
In
The field generator 50 is located external to the patient. The generator, as well as any of the electrode embodiments described herein, may be utilized with any embodiment of the present invention for delivery of a thermal electric field with desired field parameters, e.g., parameters sufficient to thermally or otherwise induce renal neuromodulation in target neural fibers via heating and/or electroporation. It should be understood that electrodes of embodiments described hereinafter may be electrically connected to the generator even though the generator is not explicitly shown or described with each embodiment. Furthermore, the field generator optionally may be positioned internal to the patient. Furtherstill, the field generator may additionally comprise or may be substituted with an alternative thermal energy generator, such as a thermoelectric generator for heating or cooling (e.g., a Peltier device), or a thermal fluid injection system for heating or cooling, etc.
The electrode(s) 212 can be individual electrodes that are electrically independent of each other, a segmented electrode with commonly connected contacts, or a continuous electrode. A segmented electrode may, for example, be formed by providing a slotted tube fitted onto the electrode, or by electrically connecting a series of individual electrodes. Individual electrodes or groups of electrodes 212 may be configured to provide a bipolar signal. The electrodes 212 may be dynamically assignable to facilitate monopolar and/or bipolar energy delivery between any of the electrodes and/or between any of the electrodes and an external ground pad. Such a ground pad may, for example, be attached externally to the patient's skin, e.g., to the patient's leg or flank. In
In
Referring now to
The positioning element 304 optionally may center or otherwise position the electrodes 306a and 306b within a vessel. Additionally, as in
Furthermore, the positioning element 304 optionally may be utilized as a cooling element and/or a heating element. For example, the positioning element 304 may be inflated with a chilled fluid that serves as a heat sink for removing heat from tissue that contacts the element. Conversely, the positioning element 304 optionally may be a heating element by inflating it with a warmed fluid that heats tissue in contact with the element. The thermal fluid optionally may be circulated and/or exchanged within the positioning element 304 to facilitate more efficient conductive and/or convective heat transfer. Thermal fluids also may be used to achieve thermal neuromodulation via thermal cooling or heating mechanisms, as described in greater detail herein below. The positioning element 304 (or any other portion of apparatus 300) additionally or alternatively may comprise one or more sensors for monitoring the process. In one embodiment, the positioning element 304 has a wall-contacting thermocouple 310 (
The electrodes 306 can be individual electrodes (i.e., independent contacts), a segmented electrode with commonly connected contacts, or a single continuous electrode. Furthermore, the electrodes 306 may be configured to provide a bipolar signal, or the electrodes 306 may be used together or individually in conjunction with a separate patient ground pad for monopolar use. As an alternative or in addition to placement of the electrodes 306 along the central shaft of the catheter 302, as in
In use, the catheter 302 may be delivered to the renal artery RA as shown, or it may be delivered to a renal vein or to any other vessel in proximity to neural tissue contributing to renal function, in a low profile delivery configuration through a guide catheter or other device. Alternatively, catheters may be positioned in multiple vessels for thermal renal neuromodulation, e.g., within both the renal artery and the renal vein. Multi-vessel techniques for pulsed electric field renal neuromodulation have been described previously, for example, in Applicants' U.S. Pat. No. 7,853,333, which is incorporated herein by reference in its entirety.
Once positioned within the renal vasculature as desired, the optional positioning element 304 may be expanded into contact with an interior wall of the vessel. A thermal electric field then may be generated by the field generator 50, transferred through the catheter 302 to the electrodes 306, and delivered via the electrodes 306 across the wall of the artery. The electric field thermally modulates the activity along neural fibers that contribute to renal function via heating. In several embodiments, the thermal modulation at least partially denervates the kidney innervated by the neural fibers via heating. This may be achieved, for example, via thermal ablation or via non-ablative damage of the target neural fibers. The electric field also may induce electroporation in the neural fibers.
In the embodiment of
Use of the patient's blood as a heat sink is expected to facilitate delivery of longer or higher energy thermal treatments with reduced risk of damage to the non-target tissue, which may enhance the efficacy of the treatment at the target neural fibers. Although the embodiment of
In addition or as an alternative to utilizing the patient's blood as a heat sink, a thermal fluid (hot or cold) may be injected into the vessel to remove excess thermal energy and protect the non-target tissues. The thermal fluid may, for example, be injected through the device catheter or through a guide catheter at a location upstream from an energy delivery element or at other locations relative to the tissue for which protection is sought. Furthermore, this method of using an injected thermal fluid to remove excess thermal energy from non-target tissues to protect the non-target tissues from thermal injury during therapeutic treatment of target tissues may be utilized in body lumens other than blood vessels.
One or more sensors, such as the thermocouple 310 of
As discussed, when utilizing intravascular apparatus to achieve thermal neuromodulation, in addition or as an alternative to central positioning of the electrode(s) within a blood vessel, the electrode(s) optionally may be configured to contact an internal wall of the blood vessel. Wall-contacting electrode(s) may facilitate more efficient transfer of a thermal electric field across the vessel wall to target neural fibers, as compared to centrally-positioned electrode(s). In some embodiments, the wall-contacting electrode(s) may be delivered to the vessel treatment site in a reduced profile configuration, then expanded in vivo to a deployed configuration wherein the electrode(s) contact the vessel wall. In some embodiments, expansion of the electrode(s) is at least partially reversible to facilitate retrieval of the electrode(s) from the patient's vessel.
As seen in
After delivery of the electric field, the electrode 306a′ may be returned to a reduced profile to facilitate removal of the apparatus 300 from the patient. For example, the positioning element 304 may be collapsed (e.g., deflated), and the electrode 306a′ may be contracted by withdrawing the catheter 302 within the guide catheter 303. Alternatively, the electrode may be fabricated from a shape-memory material biased to the collapsed configuration, such that the electrode self-collapses upon collapse of the positioning element.
Although in
A bipolar electric field may be delivered between the proximal and distal wall-contacting electrodes, or a monopolar electric field may be delivered between the proximal and/or distal electrode(s) and an external ground. Having both the proximal and distal electrodes in contact with the wall of the vessel may facilitate more efficient energy transfer across the wall during delivery of a thermal electric field, as compared to having one or both of the proximal and distal electrodes centered within the vessel.
In addition to extravascular and intravascular systems for thermally-induced renal neuromodulation, intra-to-extravascular systems may be provided. The intra-to-extravascular systems may, for example, have electrode(s) that are delivered to an intravascular position, and then at least partially passed through/across the vessel wall to an extravascular position prior to delivery of a thermal electric field. Intra-to-extravascular positioning of the electrode(s) may place the electrode(s) in closer proximity to target neural fibers for delivery of a thermal electric field, as compared to fully intravascular positioning of the electrode(s). Applicants have previously described intra-to-extravascular pulsed electric field systems, for example, in Applicants' U.S. Pat. No. 7,620,451, which is incorporated herein by reference in its entirety.
With reference to
Catheter 322 comprises an optional expandable positioning element 330, which may comprise an inflatable balloon or an expandable basket or cage. In use, the positioning element 330 may be expanded prior to deployment of the needle electrodes 328 and 329 in order to position or center the catheter 322 within the patient's vessel (e.g., within renal artery RA). Centering the catheter 322 is expected to facilitate delivery of all needle electrodes to desired depths within/external to the patient's vessel (e.g., to deliver all of the needle electrodes approximately to the same depth). In
As illustrated in
The proximal electrodes 328 can be connected to electric field generator 50 as active electrodes, and the distal electrodes 329 can serve as return electrodes. In this manner, the proximal and distal electrodes form bipolar electrode pairs that align the thermal electric field with a longitudinal axis or direction of the patient's vasculature. As will be apparent, the distal electrodes 329 alternatively may comprise the active electrodes and the proximal electrodes 328 may comprise the return electrodes. Furthermore, the proximal and/or the distal electrodes may comprise both active and return electrodes. Furtherstill, the proximal and/or the distal electrodes may be utilized in combination with an external ground for delivery of a monopolar thermal electric field. Any combination of active and distal electrodes may be utilized, as desired.
When the electrodes 328 and 329 are connected to generator 50 and positioned extravascularly, and with the positioning element 330 optionally expanded, delivery of the thermal electric field may proceed to achieve desired renal neuromodulation via heating. The electric field also may induce electroporation. After achievement of the thermally-induced renal neuromodulation, the electrodes may be retracted within the proximal and distal lumens, and the positioning element 330 may be collapsed for retrieval. ITEV system 320 then may be removed from the patient to complete the procedure. Additionally or alternatively, the system may be repositioned to provide therapy at another treatment site, such as to provide bilateral renal neuromodulation.
As discussed previously, cooling elements, such as convective cooling elements, may be utilized to protect non-target tissues like smooth muscle cells from thermal damage during thermally-induced renal neuromodulation via heat generation. Non-target tissues additionally or alternatively may be protected by focusing the thermal energy on the target neural fibers such that an intensity of the thermal energy is insufficient to induce thermal damage in non-target tissues distant from the target neural fibers.
Although
The embodiments of
With reference now to
In addition or as alternative to injection of a thermal fluid to the target neural fibers through infusion needles 328′ and 329′, an alternative neuromodulatory agent, such as a drug or medicament, may be injected to modulate, necrose or otherwise block or reduce transmission along the target neural fibers. Examples of alternative neuromodulatory agents include, but are not limited to, phenol and neurotoxins, such as botulinum toxin. Additional neuromodulatory agents, per se known, will be apparent to those of skill in the art.
An electric current is passed from the power supply to the thermoelectric element, which comprises two different metals (e.g., a p-type and an n-type semiconductor) that are connected to each other at two junctions. The current induces a thermal gradient between the two junctions, such that one junction cools while the other is heated. Reversal of the polarity of the voltage applied across the two junctions reverses the direction of the thermal gradient.
Either the hot side or the cold side of the thermoelectric element faces radially inward in order to heat or cool, respectively, the target neural fibers that travel along the renal artery to achieve thermal renal neuromodulation. Optionally, the radially outward surface of the thermoelectric element may be insulated to reduce a risk of thermal damage to the non-target tissues. The cuff 342 may comprise one or more temperature sensors, such as thermocouples, for monitoring the temperature of the target neural fibers and/or of the non-target tissues.
The pump 352 further comprises one or more thermoelectric or other thermal elements in heat exchange contact with the fluid reservoir for cooling or heating the fluid that is transferred to the cuff to thermally modulate the target neural fibers. The apparatus 350 optionally may have controls for automatic or manual control of fluid heating or cooling, as well as fluid circulation within the cuff. Furthermore, the apparatus may comprise temperature and/or renal sympathetic neural activity monitoring or feedback control. Although the apparatus illustratively is shown unilaterally treating neural fibers innervating a single kidney, it should be understood that bilateral treatment of neural fibers innervating both kidneys alternatively may be provided.
Thermal renal neuromodulation alternatively may be achieved via high-intensity focused ultrasound, either pulsed or continuous. High intensity focused ultrasound also may induce reversible or irreversible electroporation in the target neural fibers. Furthermore, the ultrasound may be delivered over a full 360° (e.g. when delivered intravascularly) or over a radial segment of less than 360° (e.g., when delivered intravascularly, extravascularly, intra-to-extravascularly, or a combination thereof). In
The focal distance may be specified or dynamically variable such that, when positioned within a blood vessel, the ultrasonic wave is focused at a desired depth on target neural fibers outside of the vessel. For example, a family of catheter sizes may be provided to allow for a range of specified focal distances. A dynamically variable focal distance may be achieved, for example, via calibrated expansion of the balloon.
Focusing the ultrasound wave may produce a reverse thermal gradient that protects the non-target tissues and selectively affect the target neural fibers to achieve thermal renal neuromodulation via heating. As a result, the temperature at the vessel wall may be less than the temperature at the target tissue.
The apparatus described above with respect to
As seen in
It is expected that thermally-induced renal neuromodulation, whether delivered extravascularly, intravascularly, intra-to-extravascularly or a combination thereof, may alleviate clinical symptoms of CHF, hypertension, renal disease, myocardial infarction, atrial fibrillation, contrast nephropathy and/or other cardio-renal diseases for a period of months, potentially up to six months or more. This time period may be sufficient to allow the body to heal; for example, this period may reduce the risk of CHF onset after an acute myocardial infarction, thereby alleviating a need for subsequent re-treatment. Alternatively, as symptoms reoccur, or at regularly scheduled intervals, the patient may receive repeat therapy.
Although preferred illustrative variations of the present invention are described above, it will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the invention. It is intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.
The present application is a continuation of U.S. patent application Ser. No. 13/765,487, filed Feb. 12, 2013, now U.S. Pat. No. 8,784,463, which is a continuation of U.S. patent application Ser. No. 12/700,524, filed Feb. 4, 2010, now U.S. Pat. No. 8,986,294, which is a continuation of U.S. patent application Ser. No. 11/840,142, filed Aug. 16, 2007, now U.S. Pat. No. 7,717,948, which is a continuation of U.S. patent application Ser. No. 11/504,117, filed Aug. 14, 2006, now U.S. Pat. No. 7,617,005, which claims the benefit of U.S. Provisional Application No. 60/816,999 filed on Jun. 28, 2006. U.S. patent application Ser. No. 11/504,117, filed Aug. 14, 2006, now U.S. Pat. No. 7,617,005 is also a Continuation-In-Part application of each of the following: (A) U.S. patent application Ser. No. 10/408,665, filed on Apr. 8, 2003, now U.S. Pat. No. 7,162,303, which claims the benefit of U.S. Provisional Application No. 60/370,190, filed on Apr. 8, 2002, U.S. Provisional Application No. 60/415,575, filed on Oct. 3, 2002, and U.S. Provisional Application No. 60/442,970, filed on Jan. 29, 2003. (B) U.S. patent application Ser. No. 11/189,563, filed on Jul. 25, 2005, now U.S. Pat. No. 8,145,316, which is a Continuation-In-Part application of U.S. patent application Ser. No. 11/129,765, filed on May 13, 2005, now U.S. Pat. No. 7,653,438, which claims the benefit of U.S. Provisional Application No. 60/616,254, filed on Oct. 5, 2004, and U.S. Provisional Application No. 60/624,793, filed on Nov. 2, 2004. All of these applications are incorporated herein by reference in their entireties. All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2130758 | Rose | Sep 1938 | A |
2276995 | Milinowski | Mar 1942 | A |
2276996 | Milinowski | Mar 1942 | A |
3043310 | Milinowski | Jul 1962 | A |
3127895 | Kendall et al. | Apr 1964 | A |
3181535 | Milinowski | May 1965 | A |
3270746 | Kendall et al. | Sep 1966 | A |
3329149 | Kendall et al. | Jul 1967 | A |
3522811 | Scchwartz et al. | Aug 1970 | A |
3563246 | Puharich et al. | Feb 1971 | A |
3650277 | Sjostrand et al. | Mar 1972 | A |
3670737 | Pearo | Jun 1972 | A |
3752162 | Newash | Aug 1973 | A |
3760812 | Timm et al. | Sep 1973 | A |
3774620 | Hansjurgens et al. | Nov 1973 | A |
3794022 | Nawracaj et al. | Feb 1974 | A |
3800802 | Berry et al. | Apr 1974 | A |
3803463 | Cover | Apr 1974 | A |
3894532 | Morey | Jul 1975 | A |
3895639 | Rodler et al. | Jul 1975 | A |
3897789 | Blanchard | Aug 1975 | A |
3911930 | Hagfors et al. | Oct 1975 | A |
3952751 | Yarger | Apr 1976 | A |
3987790 | Eckenhoff et al. | Oct 1976 | A |
4011861 | Enger | Mar 1977 | A |
4026300 | DeLuca et al. | May 1977 | A |
4055190 | Tany et al. | Oct 1977 | A |
4071033 | Nawracaj et al. | Jan 1978 | A |
4105017 | Ryaby et al. | Aug 1978 | A |
4141365 | Fischell et al. | Feb 1979 | A |
4266532 | Ryaby et al. | May 1981 | A |
4266533 | Ryaby et al. | May 1981 | A |
4305115 | Armitage et al. | Dec 1981 | A |
4315503 | Ryaby et al. | Feb 1982 | A |
4345602 | Yoshimura et al. | Aug 1982 | A |
4360019 | Portner et al. | Nov 1982 | A |
4379462 | Borkan et al. | Apr 1983 | A |
4405305 | Stephen et al. | Sep 1983 | A |
4454883 | Fellus et al. | Jun 1984 | A |
4467808 | Brighton et al. | Aug 1984 | A |
4487603 | Harris | Dec 1984 | A |
4530840 | Tice et al. | Jul 1985 | A |
4587975 | Salo et al. | May 1986 | A |
4602624 | Naples et al. | Jul 1986 | A |
4608985 | Crish et al. | Sep 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4658828 | Dory | Apr 1987 | A |
4671286 | Renault et al. | Jun 1987 | A |
4674482 | Waltonen et al. | Jun 1987 | A |
4692147 | Duggan | Sep 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4715852 | Reinicke et al. | Dec 1987 | A |
4764504 | Johnson et al. | Aug 1988 | A |
4774967 | Zanakis et al. | Oct 1988 | A |
4791931 | Slate | Dec 1988 | A |
4816016 | Schulte et al. | Mar 1989 | A |
4824436 | Wolinsky | Apr 1989 | A |
4852573 | Kennedy | Aug 1989 | A |
4858613 | Fry et al. | Aug 1989 | A |
4865845 | Eckenhoff et al. | Sep 1989 | A |
4890623 | Cook et al. | Jan 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
4981146 | Bertolucci | Jan 1991 | A |
4986275 | Ishida et al. | Jan 1991 | A |
4998532 | Griffith | Mar 1991 | A |
5006119 | Acker et al. | Apr 1991 | A |
5014699 | Pollack et al. | May 1991 | A |
5019034 | Weaver et al. | May 1991 | A |
5038789 | Frazin | Aug 1991 | A |
5057318 | Magruder et al. | Oct 1991 | A |
5058584 | Bourgeois et al. | Oct 1991 | A |
5059423 | Magruder et al. | Oct 1991 | A |
5061492 | Okada et al. | Oct 1991 | A |
5065740 | Itoh | Nov 1991 | A |
5080101 | Dory | Jan 1992 | A |
5087244 | Wolinsky et al. | Feb 1992 | A |
5094242 | Gleason et al. | Mar 1992 | A |
5102402 | Dror et al. | Apr 1992 | A |
5111815 | Mower | May 1992 | A |
5112614 | Magruder et al. | May 1992 | A |
5125928 | Parins et al. | Jun 1992 | A |
5131409 | Lobarev et al. | Jul 1992 | A |
5137727 | Eckenhoff | Aug 1992 | A |
5188837 | Domb | Feb 1993 | A |
5190045 | Frazin | Mar 1993 | A |
5193048 | Kaufman et al. | Mar 1993 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5199428 | Obel et al. | Apr 1993 | A |
5203326 | Collins et al. | Apr 1993 | A |
5213098 | Bennett et al. | May 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5234692 | Magruder et al. | Aug 1993 | A |
5234693 | Magruder et al. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5251643 | Osypka et al. | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5282468 | Klepinski | Feb 1994 | A |
5282785 | Shapland et al. | Feb 1994 | A |
5286254 | Shapland et al. | Feb 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5304120 | Crandell et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5306250 | March et al. | Apr 1994 | A |
5317155 | King | May 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5326341 | Lew et al. | Jul 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5338662 | Sadri | Aug 1994 | A |
5344395 | Whalen et al. | Sep 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5370680 | Proctor | Dec 1994 | A |
5389069 | Weaver | Feb 1995 | A |
5397308 | Ellis et al. | Mar 1995 | A |
5397338 | Grey et al. | Mar 1995 | A |
5400784 | Durand et al. | Mar 1995 | A |
5405367 | Schulman et al. | Apr 1995 | A |
5415654 | Daikuzono | May 1995 | A |
5419767 | Eggers et al. | May 1995 | A |
5419777 | Hofling | May 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5425364 | Imran | Jun 1995 | A |
5429634 | Narciso, Jr. | Jul 1995 | A |
5433739 | Sluijter et al. | Jul 1995 | A |
5439440 | Hofmann | Aug 1995 | A |
5454782 | Perkins | Oct 1995 | A |
5454809 | Janssen | Oct 1995 | A |
5458568 | Racchini et al. | Oct 1995 | A |
5458626 | Krause | Oct 1995 | A |
5458631 | Xavier | Oct 1995 | A |
5464395 | Faxon et al. | Nov 1995 | A |
5470352 | Rappaport | Nov 1995 | A |
5471988 | Fujio et al. | Dec 1995 | A |
5472406 | de la Torre et al. | Dec 1995 | A |
5478303 | Foley-Nolan et al. | Dec 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5494822 | Sadri | Feb 1996 | A |
5498238 | Shapland et al. | Mar 1996 | A |
5499971 | Shapland et al. | Mar 1996 | A |
5505700 | Leone et al. | Apr 1996 | A |
5507724 | Hofmann et al. | Apr 1996 | A |
5507791 | Sit'ko et al. | Apr 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5538504 | Linden et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5553611 | Budd et al. | Sep 1996 | A |
5560360 | Filler et al. | Oct 1996 | A |
5569198 | Racchini | Oct 1996 | A |
5571147 | Sluijter et al. | Nov 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5573552 | Hansjurgens et al. | Nov 1996 | A |
5584863 | Rauch et al. | Dec 1996 | A |
5588434 | Fujimoto | Dec 1996 | A |
5588960 | Edwards et al. | Dec 1996 | A |
5588962 | Nicholas et al. | Dec 1996 | A |
5588964 | Imran et al. | Dec 1996 | A |
5589192 | Okabe et al. | Dec 1996 | A |
5590654 | Prince | Jan 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5618563 | Berde et al. | Apr 1997 | A |
5626576 | Janssen | May 1997 | A |
5626862 | Brem et al. | May 1997 | A |
5628730 | Shapland et al. | May 1997 | A |
5634462 | Tyler et al. | Jun 1997 | A |
5634899 | Shapland et al. | Jun 1997 | A |
5667490 | Keith et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5689877 | Grill, Jr. et al. | Nov 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5700485 | Berde et al. | Dec 1997 | A |
5704908 | Hofmann et al. | Jan 1998 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5709874 | Hanson et al. | Jan 1998 | A |
5711326 | Thies et al. | Jan 1998 | A |
5713847 | Howard, III et al. | Feb 1998 | A |
5722401 | Pietroski et al. | Mar 1998 | A |
5723001 | Pilla et al. | Mar 1998 | A |
5725563 | Klotz et al. | Mar 1998 | A |
5728396 | Peery et al. | Mar 1998 | A |
5747060 | Sackler et al. | May 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5756115 | Moo-Young et al. | May 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5779644 | Eberle et al. | Jul 1998 | A |
5792187 | Adams | Aug 1998 | A |
5800464 | Kieval | Sep 1998 | A |
5807306 | Shapland et al. | Sep 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5814079 | Kieval | Sep 1998 | A |
5817144 | Gregory | Oct 1998 | A |
5824087 | Aspden et al. | Oct 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
RE35987 | Harris et al. | Dec 1998 | E |
5843016 | Lugnani et al. | Dec 1998 | A |
5843069 | Butler et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5861021 | Thome et al. | Jan 1999 | A |
5865787 | Shapland et al. | Feb 1999 | A |
5865801 | Houser | Feb 1999 | A |
5871449 | Brown | Feb 1999 | A |
5876374 | Alba et al. | Mar 1999 | A |
5891181 | Zhu et al. | Apr 1999 | A |
5893885 | Webster et al. | Apr 1999 | A |
5906636 | Casscells, III et al. | May 1999 | A |
5906817 | Moullier et al. | May 1999 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916154 | Hobbs et al. | Jun 1999 | A |
5916227 | Keith et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919187 | Guglielmi et al. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5924997 | Campbell | Jul 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5935075 | Casscells et al. | Aug 1999 | A |
5938670 | Keith et al. | Aug 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5983131 | Weaver et al. | Nov 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
5989208 | Nita | Nov 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6010613 | Walters et al. | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6026326 | Bardy | Feb 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6041252 | Walker et al. | Mar 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6058328 | Levine et al. | May 2000 | A |
6058331 | King | May 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6077227 | Miesel et al. | Jun 2000 | A |
6086527 | Talpade | Jul 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6117128 | Gregory | Sep 2000 | A |
6122548 | Starkebaum et al. | Sep 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6135999 | Fanton et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6146380 | Racz et al. | Nov 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6171306 | Swanson et al. | Jan 2001 | B1 |
6178349 | Kieval | Jan 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6192889 | Morrish | Feb 2001 | B1 |
6205361 | Kuzma et al. | Mar 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6210356 | Anderson et al. | Apr 2001 | B1 |
6211247 | Goodman | Apr 2001 | B1 |
6214032 | Loeb et al. | Apr 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6238702 | Berde et al. | May 2001 | B1 |
6245026 | Campbell et al. | Jun 2001 | B1 |
6245045 | Stratienko | Jun 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6251130 | Dobak, III et al. | Jun 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6259952 | Sluijter et al. | Jul 2001 | B1 |
6269269 | Ottenhoff et al. | Jul 2001 | B1 |
6272377 | Sweeney et al. | Aug 2001 | B1 |
6272383 | Grey et al. | Aug 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6280377 | Talpade | Aug 2001 | B1 |
6283947 | Mirzaee | Sep 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6287304 | Eggers et al. | Sep 2001 | B1 |
6287608 | Levin et al. | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6302870 | Jacobsen et al. | Oct 2001 | B1 |
6304777 | Ben-Haim et al. | Oct 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6306423 | Donovan et al. | Oct 2001 | B1 |
6309379 | Willard et al. | Oct 2001 | B1 |
6314325 | Fitz | Nov 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6326020 | Kohane et al. | Dec 2001 | B1 |
6326177 | Schoenbach et al. | Dec 2001 | B1 |
6328699 | Eigler et al. | Dec 2001 | B1 |
6334069 | George et al. | Dec 2001 | B1 |
6347247 | Dev et al. | Feb 2002 | B1 |
6353763 | George et al. | Mar 2002 | B1 |
6356786 | Rezai et al. | Mar 2002 | B1 |
6356787 | Rezai et al. | Mar 2002 | B1 |
6366808 | Schroeppel et al. | Apr 2002 | B1 |
6366815 | Haugland et al. | Apr 2002 | B1 |
6379373 | Sawhney et al. | Apr 2002 | B1 |
6389314 | Feiring | May 2002 | B2 |
6393324 | Gruzdowich et al. | May 2002 | B2 |
6400982 | Sweeney et al. | Jun 2002 | B2 |
6405079 | Ansarinia | Jun 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6415183 | Scheiner et al. | Jul 2002 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6438423 | Rezai et al. | Aug 2002 | B1 |
6442424 | Ben-Haim et al. | Aug 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6450942 | Lapanashvili et al. | Sep 2002 | B1 |
6461314 | Pant et al. | Oct 2002 | B1 |
6464687 | Ishikawa et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6482619 | Rubinsky et al. | Nov 2002 | B1 |
6484052 | Visuri et al. | Nov 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6508774 | Acker et al. | Jan 2003 | B1 |
6514226 | Levin et al. | Feb 2003 | B1 |
6514236 | Stratienko | Feb 2003 | B1 |
6516211 | Acker et al. | Feb 2003 | B1 |
6517811 | John et al. | Feb 2003 | B2 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6522932 | Kuzma et al. | Feb 2003 | B1 |
6524274 | Rosenthal et al. | Feb 2003 | B1 |
6524607 | Goldenheim et al. | Feb 2003 | B1 |
6534081 | Goldenheim et al. | Mar 2003 | B2 |
6536949 | Heuser | Mar 2003 | B1 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6546934 | Ingle et al. | Apr 2003 | B1 |
6547767 | Moein | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6558382 | Jahns et al. | May 2003 | B2 |
6564096 | Mest | May 2003 | B2 |
6571127 | Ben-Haim et al. | May 2003 | B1 |
6592567 | Levin et al. | Jul 2003 | B1 |
6595959 | Stratienko | Jul 2003 | B1 |
6599256 | Acker et al. | Jul 2003 | B1 |
6600954 | Cohen et al. | Jul 2003 | B2 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6601459 | Jenni | Aug 2003 | B1 |
6605084 | Acker et al. | Aug 2003 | B2 |
6613045 | Laufer et al. | Sep 2003 | B1 |
6615071 | Casscells, III et al. | Sep 2003 | B1 |
6616624 | Kieval | Sep 2003 | B1 |
6620151 | Blischak et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622731 | Daniel et al. | Sep 2003 | B2 |
6623452 | Chien et al. | Sep 2003 | B2 |
6623453 | Guibert et al. | Sep 2003 | B1 |
6632196 | Houser | Oct 2003 | B1 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6654636 | Dev et al. | Nov 2003 | B1 |
6666845 | Hooper et al. | Dec 2003 | B2 |
6669655 | Acker et al. | Dec 2003 | B1 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6672312 | Acker | Jan 2004 | B2 |
6676657 | Wood | Jan 2004 | B2 |
6681136 | Schuler et al. | Jan 2004 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6689086 | Nita et al. | Feb 2004 | B1 |
6689148 | Sawhney et al. | Feb 2004 | B2 |
6690971 | Schauerte et al. | Feb 2004 | B2 |
6692738 | MacLaughlin et al. | Feb 2004 | B2 |
6695830 | Vigil et al. | Feb 2004 | B2 |
6697670 | Chomenky et al. | Feb 2004 | B2 |
6699231 | Sterman et al. | Mar 2004 | B1 |
6706011 | Murphy-Chutorian et al. | Mar 2004 | B1 |
6711444 | Koblish | Mar 2004 | B2 |
6714822 | King et al. | Mar 2004 | B2 |
6718208 | Hill et al. | Apr 2004 | B2 |
6723064 | Babaev | Apr 2004 | B2 |
6735471 | Hill et al. | May 2004 | B2 |
6738663 | Schroeppel et al. | May 2004 | B2 |
6749598 | Keren et al. | Jun 2004 | B1 |
6752805 | Maguire et al. | Jun 2004 | B2 |
6767544 | Brooks et al. | Jul 2004 | B2 |
6780183 | Jimenez, Jr. et al. | Aug 2004 | B2 |
6786904 | Doscher et al. | Sep 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6795728 | Chornenky et al. | Sep 2004 | B2 |
6814730 | Li | Nov 2004 | B2 |
6830568 | Kesten et al. | Dec 2004 | B1 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6850801 | Kieval et al. | Feb 2005 | B2 |
6862479 | Whitehurst et al. | Mar 2005 | B1 |
6865416 | Dev et al. | Mar 2005 | B2 |
6866662 | Fuimaono et al. | Mar 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6893414 | Goble et al. | May 2005 | B2 |
6916656 | Walters et al. | Jul 2005 | B2 |
6927049 | Rubinsky et al. | Aug 2005 | B2 |
6936047 | Nasab et al. | Aug 2005 | B2 |
6939345 | KenKnight et al. | Sep 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6953460 | Maguire et al. | Oct 2005 | B2 |
6954977 | Maguire et al. | Oct 2005 | B2 |
6958060 | Mathiesen et al. | Oct 2005 | B2 |
6969388 | Goldman et al. | Nov 2005 | B2 |
6972013 | Zhang et al. | Dec 2005 | B1 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
6985774 | Kieval et al. | Jan 2006 | B2 |
6991617 | Hektner et al. | Jan 2006 | B2 |
6994700 | Elkins et al. | Feb 2006 | B2 |
6994706 | Chornenky et al. | Feb 2006 | B2 |
7004911 | Tu et al. | Feb 2006 | B1 |
7054685 | Dimmer et al. | May 2006 | B2 |
7063679 | Maguire et al. | Jun 2006 | B2 |
7066904 | Rosenthal et al. | Jun 2006 | B2 |
7074233 | Gowda et al. | Jul 2006 | B1 |
7081114 | Rashidi | Jul 2006 | B2 |
7081115 | Taimisto | Jul 2006 | B2 |
7083614 | Fjield et al. | Aug 2006 | B2 |
7122019 | Kesten et al. | Oct 2006 | B1 |
7127284 | Seward | Oct 2006 | B2 |
7141041 | Seward | Nov 2006 | B2 |
7155284 | Whitehurst et al. | Dec 2006 | B1 |
7162303 | Levin et al. | Jan 2007 | B2 |
7191015 | Lamson et al. | Mar 2007 | B2 |
7197354 | Sobe | Mar 2007 | B2 |
7241273 | Maguire et al. | Jul 2007 | B2 |
7241736 | Hunter et al. | Jul 2007 | B2 |
7273469 | Chan et al. | Sep 2007 | B1 |
7297475 | Koiwai et al. | Nov 2007 | B2 |
7326235 | Edwards | Feb 2008 | B2 |
7329236 | Kesten et al. | Feb 2008 | B2 |
7335192 | Keren et al. | Feb 2008 | B2 |
7364566 | Elkins et al. | Apr 2008 | B2 |
7373204 | Gelfand et al. | May 2008 | B2 |
7381200 | Katoh et al. | Jun 2008 | B2 |
7407671 | McBride et al. | Aug 2008 | B2 |
7413556 | Zhang et al. | Aug 2008 | B2 |
7444183 | Knudson et al. | Oct 2008 | B2 |
7465298 | Seward et al. | Dec 2008 | B2 |
7481803 | Kesten et al. | Jan 2009 | B2 |
7485104 | Kieval | Feb 2009 | B2 |
7507235 | Keogh et al. | Mar 2009 | B2 |
7529589 | Williams et al. | May 2009 | B2 |
7540870 | Babaev | Jun 2009 | B2 |
7558625 | Levin et al. | Jul 2009 | B2 |
7563247 | Maguire et al. | Jul 2009 | B2 |
7599730 | Hunter et al. | Oct 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7640046 | Pastore et al. | Dec 2009 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7666163 | Seward et al. | Feb 2010 | B2 |
7691080 | Seward et al. | Apr 2010 | B2 |
7706882 | Francischelli et al. | Apr 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7744584 | Seward et al. | Jun 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7766892 | Keren et al. | Aug 2010 | B2 |
7837720 | Mon | Nov 2010 | B2 |
7905862 | Sampson | Mar 2011 | B2 |
7917208 | Yomtov et al. | Mar 2011 | B2 |
8016786 | Seward et al. | Sep 2011 | B2 |
8027740 | Altman et al. | Sep 2011 | B2 |
8119183 | O'Donoghue et al. | Feb 2012 | B2 |
8131371 | Demarais et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8145316 | Deem et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8162933 | Francischelli et al. | Apr 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
8257724 | Cromack et al. | Sep 2012 | B2 |
8257725 | Cromack et al. | Sep 2012 | B2 |
8263104 | Ho et al. | Sep 2012 | B2 |
8317776 | Ferren et al. | Nov 2012 | B2 |
8388680 | Starksen et al. | Mar 2013 | B2 |
8396548 | Perry et al. | Mar 2013 | B2 |
8399443 | Seward | Mar 2013 | B2 |
8403881 | Ferren et al. | Mar 2013 | B2 |
8444640 | Demarais et al. | May 2013 | B2 |
8465752 | Seward | Jun 2013 | B2 |
8562573 | Fischell | Oct 2013 | B1 |
8620423 | Demarais et al. | Dec 2013 | B2 |
8663190 | Fischell et al. | Mar 2014 | B2 |
8684998 | Demarais et al. | Apr 2014 | B2 |
8708995 | Seward et al. | Apr 2014 | B2 |
8721590 | Seward et al. | May 2014 | B2 |
8728137 | Zarins et al. | May 2014 | B2 |
8728138 | Zarins et al. | May 2014 | B2 |
8740849 | Fischell et al. | Jun 2014 | B1 |
8740895 | Mayse et al. | Jun 2014 | B2 |
8774913 | Demarais et al. | Jul 2014 | B2 |
8777943 | Mayse et al. | Jul 2014 | B2 |
8852163 | Deem | Oct 2014 | B2 |
8975233 | Stein et al. | Mar 2015 | B2 |
9011879 | Seward | Apr 2015 | B2 |
9033917 | Magana et al. | May 2015 | B2 |
9055956 | McRae et al. | Jun 2015 | B2 |
9056184 | Stein et al. | Jun 2015 | B2 |
9056185 | Fischell et al. | Jun 2015 | B2 |
9108030 | Braga | Aug 2015 | B2 |
9114123 | Azamian et al. | Aug 2015 | B2 |
9131983 | Fischell et al. | Sep 2015 | B2 |
9179962 | Fischell et al. | Nov 2015 | B2 |
9199065 | Seward | Dec 2015 | B2 |
9237925 | Fischell et al. | Jan 2016 | B2 |
9265558 | Zarins | Feb 2016 | B2 |
9278196 | Fischell et al. | Mar 2016 | B2 |
9320850 | Fischell et al. | Apr 2016 | B2 |
9526827 | Fischell et al. | Dec 2016 | B2 |
9539047 | Fischell et al. | Jan 2017 | B2 |
9554849 | Fischell et al. | Jan 2017 | B2 |
9636174 | Zarins | May 2017 | B2 |
20010039419 | Francischelli et al. | Nov 2001 | A1 |
20010044596 | Jaafar | Nov 2001 | A1 |
20020002329 | Avitall | Jan 2002 | A1 |
20020002349 | Flaherty et al. | Jan 2002 | A1 |
20020026222 | Schauerte et al. | Feb 2002 | A1 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020032468 | Hill et al. | Mar 2002 | A1 |
20020038137 | Stein | Mar 2002 | A1 |
20020040204 | Dev et al. | Apr 2002 | A1 |
20020045853 | Dev et al. | Apr 2002 | A1 |
20020065541 | Fredricks et al. | May 2002 | A1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020077592 | Barry | Jun 2002 | A1 |
20020082552 | Ding et al. | Jun 2002 | A1 |
20020087156 | Maguire et al. | Jul 2002 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020103445 | Randert et al. | Aug 2002 | A1 |
20020107515 | Edwards et al. | Aug 2002 | A1 |
20020107553 | Hill et al. | Aug 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020120304 | Mest | Aug 2002 | A1 |
20020138075 | Edwards et al. | Sep 2002 | A1 |
20020139379 | Edwards et al. | Oct 2002 | A1 |
20020165532 | Hill et al. | Nov 2002 | A1 |
20020165586 | Hill et al. | Nov 2002 | A1 |
20020169413 | Keren et al. | Nov 2002 | A1 |
20020177846 | Mulier et al. | Nov 2002 | A1 |
20020183682 | Darvish et al. | Dec 2002 | A1 |
20020183684 | Dev et al. | Dec 2002 | A1 |
20020188325 | Hill et al. | Dec 2002 | A1 |
20020198512 | Seward | Dec 2002 | A1 |
20030004549 | Hill et al. | Jan 2003 | A1 |
20030009145 | Struijker-Boudier et al. | Jan 2003 | A1 |
20030013971 | Makin et al. | Jan 2003 | A1 |
20030018367 | DiLorenzo | Jan 2003 | A1 |
20030040774 | Terry et al. | Feb 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030050635 | Truckai et al. | Mar 2003 | A1 |
20030050681 | Pianca et al. | Mar 2003 | A1 |
20030055421 | West et al. | Mar 2003 | A1 |
20030060848 | Kieval et al. | Mar 2003 | A1 |
20030060857 | Perrson et al. | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030069619 | Fenn et al. | Apr 2003 | A1 |
20030069620 | Li | Apr 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030082225 | Mason | May 2003 | A1 |
20030083653 | Maguire et al. | May 2003 | A1 |
20030100924 | Foreman et al. | May 2003 | A1 |
20030114791 | Rosenthal et al. | Jun 2003 | A1 |
20030120270 | Acker | Jun 2003 | A1 |
20030125790 | Fastovsky et al. | Jul 2003 | A1 |
20030150464 | Casscells | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030176816 | Maguire et al. | Sep 2003 | A1 |
20030178032 | Ingle et al. | Sep 2003 | A1 |
20030181897 | Thomas et al. | Sep 2003 | A1 |
20030181963 | Pellegrino et al. | Sep 2003 | A1 |
20030181965 | Levy et al. | Sep 2003 | A1 |
20030195496 | Maguire et al. | Oct 2003 | A1 |
20030195507 | Stewart et al. | Oct 2003 | A1 |
20030199747 | Michlitsch et al. | Oct 2003 | A1 |
20030199767 | Cespedes et al. | Oct 2003 | A1 |
20030199768 | Cespedes et al. | Oct 2003 | A1 |
20030199806 | Kieval | Oct 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20030204161 | Ferek-Petric | Oct 2003 | A1 |
20030216721 | Diederich et al. | Nov 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030220521 | Reitz et al. | Nov 2003 | A1 |
20030229340 | Sherry et al. | Dec 2003 | A1 |
20030233099 | Danaek et al. | Dec 2003 | A1 |
20030236443 | Cespedes et al. | Dec 2003 | A1 |
20040008978 | Lin | Jan 2004 | A1 |
20040010289 | Biggs et al. | Jan 2004 | A1 |
20040010303 | Bolea et al. | Jan 2004 | A1 |
20040019349 | Fuimaono et al. | Jan 2004 | A1 |
20040019364 | Kieval et al. | Jan 2004 | A1 |
20040019371 | Jaafar et al. | Jan 2004 | A1 |
20040043030 | Griffiths et al. | Mar 2004 | A1 |
20040054367 | Jimenez et al. | Mar 2004 | A1 |
20040062852 | Schroeder et al. | Apr 2004 | A1 |
20040064090 | Keren et al. | Apr 2004 | A1 |
20040064091 | Keren et al. | Apr 2004 | A1 |
20040064093 | Hektner et al. | Apr 2004 | A1 |
20040065615 | Hooper et al. | Apr 2004 | A1 |
20040073238 | Makower | Apr 2004 | A1 |
20040082978 | Harrison et al. | Apr 2004 | A1 |
20040101523 | Reitz et al. | May 2004 | A1 |
20040106953 | Yomtov et al. | Jun 2004 | A1 |
20040111080 | Harper et al. | Jun 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040147921 | Edwards et al. | Jul 2004 | A1 |
20040162590 | Whitehurst et al. | Aug 2004 | A1 |
20040163655 | Gelfand et al. | Aug 2004 | A1 |
20040167415 | Gelfand et al. | Aug 2004 | A1 |
20040167509 | Taimisto | Aug 2004 | A1 |
20040176699 | Walker et al. | Sep 2004 | A1 |
20040176757 | Sinelnikov et al. | Sep 2004 | A1 |
20040181178 | Aldrich et al. | Sep 2004 | A1 |
20040186468 | Edwards | Sep 2004 | A1 |
20040193228 | Gerber | Sep 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20040220511 | Scott et al. | Nov 2004 | A1 |
20040243102 | Berg et al. | Dec 2004 | A1 |
20040243206 | Tadlock | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20040253304 | Gross et al. | Dec 2004 | A1 |
20040254616 | Rossing et al. | Dec 2004 | A1 |
20040260277 | Maguire | Dec 2004 | A1 |
20050004522 | Katoh et al. | Jan 2005 | A1 |
20050010263 | Schauerte | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050038409 | Segal et al. | Feb 2005 | A1 |
20050049542 | Sigg et al. | Mar 2005 | A1 |
20050065562 | Rezai | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065574 | Rezai | Mar 2005 | A1 |
20050075681 | Rezai et al. | Apr 2005 | A1 |
20050080409 | Young et al. | Apr 2005 | A1 |
20050080459 | Jacobson et al. | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050096710 | Kieval | May 2005 | A1 |
20050113822 | Fuimaono et al. | May 2005 | A1 |
20050149173 | Hunter et al. | Jul 2005 | A1 |
20050149175 | Hunter et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154418 | Kieval et al. | Jul 2005 | A1 |
20050154445 | Hunter et al. | Jul 2005 | A1 |
20050154453 | Hunter et al. | Jul 2005 | A1 |
20050154454 | Hunter et al. | Jul 2005 | A1 |
20050165467 | Hunter et al. | Jul 2005 | A1 |
20050171523 | Rubinsky et al. | Aug 2005 | A1 |
20050171574 | Rubinsky et al. | Aug 2005 | A1 |
20050171575 | Dev et al. | Aug 2005 | A1 |
20050175661 | Hunter et al. | Aug 2005 | A1 |
20050175662 | Hunter et al. | Aug 2005 | A1 |
20050177103 | Hunter et al. | Aug 2005 | A1 |
20050181004 | Hunter et al. | Aug 2005 | A1 |
20050182479 | Bonsignore et al. | Aug 2005 | A1 |
20050186242 | Hunter et al. | Aug 2005 | A1 |
20050186243 | Hunter et al. | Aug 2005 | A1 |
20050187579 | Danek et al. | Aug 2005 | A1 |
20050192638 | Gelfand et al. | Sep 2005 | A1 |
20050197624 | Goodson et al. | Sep 2005 | A1 |
20050209548 | Dev et al. | Sep 2005 | A1 |
20050209642 | Palti | Sep 2005 | A1 |
20050228286 | Messerly et al. | Oct 2005 | A1 |
20050228460 | Levin et al. | Oct 2005 | A1 |
20050234437 | Baxter et al. | Oct 2005 | A1 |
20050234523 | Levin et al. | Oct 2005 | A1 |
20050240126 | Foley et al. | Oct 2005 | A1 |
20050240173 | Palti | Oct 2005 | A1 |
20050240228 | Palti | Oct 2005 | A1 |
20050240241 | Yun et al. | Oct 2005 | A1 |
20050245882 | Elkins et al. | Nov 2005 | A1 |
20050245892 | Elkins et al. | Nov 2005 | A1 |
20050251212 | Kieval et al. | Nov 2005 | A1 |
20050261672 | Deem et al. | Nov 2005 | A1 |
20050267010 | Goodson et al. | Dec 2005 | A1 |
20050267556 | Shuros et al. | Dec 2005 | A1 |
20050282284 | Rubinsky et al. | Dec 2005 | A1 |
20050283195 | Pastore et al. | Dec 2005 | A1 |
20050288730 | Deem et al. | Dec 2005 | A1 |
20060004417 | Rossing et al. | Jan 2006 | A1 |
20060004430 | Rossing et al. | Jan 2006 | A1 |
20060018949 | Ammon et al. | Jan 2006 | A1 |
20060025821 | Gelfand et al. | Feb 2006 | A1 |
20060030814 | Valencia et al. | Feb 2006 | A1 |
20060036218 | Goodson et al. | Feb 2006 | A1 |
20060041277 | Deem et al. | Feb 2006 | A1 |
20060041283 | Gelfand et al. | Feb 2006 | A1 |
20060058678 | Vitek et al. | Mar 2006 | A1 |
20060058711 | Harhen et al. | Mar 2006 | A1 |
20060067972 | Kesten et al. | Mar 2006 | A1 |
20060069323 | Elkins et al. | Mar 2006 | A1 |
20060074453 | Kieval et al. | Apr 2006 | A1 |
20060079859 | Elkins et al. | Apr 2006 | A1 |
20060084966 | Maguire et al. | Apr 2006 | A1 |
20060085046 | Rezai et al. | Apr 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060089674 | Walters et al. | Apr 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060100618 | Chan et al. | May 2006 | A1 |
20060100667 | Machado et al. | May 2006 | A1 |
20060106429 | Libbus et al. | May 2006 | A1 |
20060111672 | Seward | May 2006 | A1 |
20060111754 | Rezai et al. | May 2006 | A1 |
20060116720 | Knoblich | Jun 2006 | A1 |
20060121016 | Lee | Jun 2006 | A1 |
20060121610 | Rubinsky et al. | Jun 2006 | A1 |
20060135998 | Libbus et al. | Jun 2006 | A1 |
20060136004 | Cowan et al. | Jun 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060155344 | Rezai et al. | Jul 2006 | A1 |
20060167437 | Valencia | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060167499 | Palti | Jul 2006 | A1 |
20060189941 | Seward et al. | Aug 2006 | A1 |
20060189960 | Kesten et al. | Aug 2006 | A1 |
20060190044 | Libbus et al. | Aug 2006 | A1 |
20060206149 | Yun | Sep 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060212078 | Demarais et al. | Sep 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060235474 | Demarais | Oct 2006 | A1 |
20060240070 | Cromack et al. | Oct 2006 | A1 |
20060263393 | Demopulos et al. | Nov 2006 | A1 |
20060265014 | Demarais et al. | Nov 2006 | A1 |
20060265015 | Demarais et al. | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20060276852 | Demarais et al. | Dec 2006 | A1 |
20060280858 | Kokish | Dec 2006 | A1 |
20070055328 | Mayse et al. | Mar 2007 | A1 |
20070066957 | Demarais et al. | Mar 2007 | A1 |
20070066959 | Seward | Mar 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070078620 | Seward et al. | Apr 2007 | A1 |
20070083239 | Demarais et al. | Apr 2007 | A1 |
20070100318 | Seward et al. | May 2007 | A1 |
20070106249 | Seward et al. | May 2007 | A1 |
20070106250 | Seward et al. | May 2007 | A1 |
20070106251 | Seward et al. | May 2007 | A1 |
20070106255 | Seward et al. | May 2007 | A1 |
20070106256 | Seward et al. | May 2007 | A1 |
20070106257 | Seward et al. | May 2007 | A1 |
20070118107 | Francischelli et al. | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070129761 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070142864 | Libbus et al. | Jun 2007 | A1 |
20070156200 | Kornet et al. | Jul 2007 | A1 |
20070173899 | Levin et al. | Jul 2007 | A1 |
20070207186 | Scanlon et al. | Sep 2007 | A1 |
20070208134 | Hunter et al. | Sep 2007 | A1 |
20070208291 | Patel | Sep 2007 | A1 |
20070208382 | Yun | Sep 2007 | A1 |
20070219576 | Cangialosi | Sep 2007 | A1 |
20070248639 | Demopulos et al. | Oct 2007 | A1 |
20070254833 | Hunter et al. | Nov 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20070269385 | Yun et al. | Nov 2007 | A1 |
20070278103 | Hoerr et al. | Dec 2007 | A1 |
20070282376 | Shuros et al. | Dec 2007 | A1 |
20070282407 | Demarais et al. | Dec 2007 | A1 |
20070288070 | Libbus et al. | Dec 2007 | A1 |
20070299043 | Hunter et al. | Dec 2007 | A1 |
20080004596 | Yun et al. | Jan 2008 | A1 |
20080004673 | Rossing et al. | Jan 2008 | A1 |
20080015659 | Zhang et al. | Jan 2008 | A1 |
20080039746 | Hissong et al. | Feb 2008 | A1 |
20080039904 | Bulkes et al. | Feb 2008 | A1 |
20080045890 | Seward et al. | Feb 2008 | A1 |
20080086072 | Bonutti et al. | Apr 2008 | A1 |
20080091255 | Caparso et al. | Apr 2008 | A1 |
20080140150 | Zhou et al. | Jun 2008 | A1 |
20080208162 | Joshi | Aug 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20080221551 | Goodson et al. | Sep 2008 | A1 |
20080245371 | Gruber | Oct 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20080317818 | Griffith et al. | Dec 2008 | A1 |
20080319513 | Pu et al. | Dec 2008 | A1 |
20090024195 | Rezai et al. | Jan 2009 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090062873 | Wu et al. | Mar 2009 | A1 |
20090074828 | Alexis et al. | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090105631 | Kieval | Apr 2009 | A1 |
20090142306 | Seward et al. | Jun 2009 | A1 |
20090156988 | Ferren et al. | Jun 2009 | A1 |
20090157057 | Ferren et al. | Jun 2009 | A1 |
20090216317 | Cromack et al. | Aug 2009 | A1 |
20090221955 | Babaev | Sep 2009 | A1 |
20100010567 | Deem et al. | Jan 2010 | A1 |
20100057150 | Demarais et al. | Mar 2010 | A1 |
20100069837 | Rassat et al. | Mar 2010 | A1 |
20100087782 | Ghaffari et al. | Apr 2010 | A1 |
20100087809 | Edwards et al. | Apr 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100168731 | Wu et al. | Jul 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100174282 | Demarais et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100217162 | Hissong et al. | Aug 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100228122 | Keenan et al. | Sep 2010 | A1 |
20100249702 | Magana et al. | Sep 2010 | A1 |
20100249773 | Clark et al. | Sep 2010 | A1 |
20100268307 | Demarais et al. | Oct 2010 | A1 |
20100324472 | Wulfman | Dec 2010 | A1 |
20110060324 | Wu et al. | Mar 2011 | A1 |
20110104060 | Seward | May 2011 | A1 |
20110104061 | Seward | May 2011 | A1 |
20110112400 | Emery et al. | May 2011 | A1 |
20110137155 | Weber et al. | Jun 2011 | A1 |
20110137298 | Nguyen et al. | Jun 2011 | A1 |
20110178570 | Demarais | Jul 2011 | A1 |
20110182912 | Evans et al. | Jul 2011 | A1 |
20110184337 | Evans et al. | Jul 2011 | A1 |
20110200171 | Beetel et al. | Aug 2011 | A1 |
20110202098 | Demarais et al. | Aug 2011 | A1 |
20110208096 | Demarais et al. | Aug 2011 | A1 |
20110257564 | Demarais et al. | Oct 2011 | A1 |
20110257622 | Salahieh et al. | Oct 2011 | A1 |
20110257647 | Mayse et al. | Oct 2011 | A1 |
20110264011 | Wu et al. | Oct 2011 | A1 |
20110264075 | Leung et al. | Oct 2011 | A1 |
20110301587 | Deem et al. | Dec 2011 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120172837 | Demarais | Jul 2012 | A1 |
20120209261 | Mayse et al. | Aug 2012 | A1 |
20120259269 | Meyer | Oct 2012 | A1 |
20120271277 | Fischell et al. | Oct 2012 | A1 |
20120271301 | Fischell et al. | Oct 2012 | A1 |
20120310233 | Dimmer et al. | Dec 2012 | A1 |
20130006232 | Pellegrino et al. | Jan 2013 | A1 |
20130012844 | Demarais et al. | Jan 2013 | A1 |
20130053792 | Fischell et al. | Feb 2013 | A1 |
20130053821 | Fischell et al. | Feb 2013 | A1 |
20130053822 | Fischell et al. | Feb 2013 | A1 |
20130096604 | Hanson et al. | Apr 2013 | A1 |
20130131668 | Schaer | May 2013 | A1 |
20130158441 | Demarais et al. | Jun 2013 | A1 |
20130158442 | Demarais et al. | Jun 2013 | A1 |
20130165822 | Demarais et al. | Jun 2013 | A1 |
20130172815 | Perry et al. | Jul 2013 | A1 |
20130204131 | Seward | Aug 2013 | A1 |
20130252932 | Seward | Sep 2013 | A1 |
20130274673 | Fischell et al. | Oct 2013 | A1 |
20130274674 | Fischell et al. | Oct 2013 | A1 |
20130287698 | Seward | Oct 2013 | A1 |
20130296853 | Sugimoto et al. | Nov 2013 | A1 |
20130317497 | Edwards et al. | Nov 2013 | A1 |
20140012231 | Fischell | Jan 2014 | A1 |
20140046298 | Fischell et al. | Feb 2014 | A1 |
20140058294 | Gross et al. | Feb 2014 | A1 |
20140107478 | Seward et al. | Apr 2014 | A1 |
20140121641 | Fischell et al. | May 2014 | A1 |
20140121644 | Fischell et al. | May 2014 | A1 |
20140135661 | Garrison et al. | May 2014 | A1 |
20140236103 | Fischell et al. | Aug 2014 | A1 |
20140271717 | Goshayeshgar et al. | Sep 2014 | A1 |
20140276621 | Braga | Sep 2014 | A1 |
20140296279 | Seward et al. | Oct 2014 | A1 |
20140303569 | Seward et al. | Oct 2014 | A1 |
20140316351 | Fischell et al. | Oct 2014 | A1 |
20140358079 | Fischell et al. | Dec 2014 | A1 |
20140378906 | Fischell et al. | Dec 2014 | A1 |
20150005719 | Fischell et al. | Jan 2015 | A1 |
20150132409 | Stein et al. | May 2015 | A1 |
20150202220 | Stein et al. | Jul 2015 | A1 |
20150224289 | Seward | Aug 2015 | A1 |
20150231386 | Meyer | Aug 2015 | A1 |
20150245863 | Fischell et al. | Sep 2015 | A1 |
20150335384 | Fischell et al. | Nov 2015 | A1 |
20150343156 | Fischell et al. | Dec 2015 | A1 |
20150343175 | Braga | Dec 2015 | A1 |
20160008387 | Stein et al. | Jan 2016 | A9 |
20160051465 | Azamian et al. | Feb 2016 | A1 |
20160058489 | Fischell et al. | Mar 2016 | A1 |
20160120587 | Fischell et al. | May 2016 | A1 |
20160235464 | Fischell et al. | Aug 2016 | A1 |
20160242661 | Fischell et al. | Aug 2016 | A1 |
20160310200 | Wang | Oct 2016 | A1 |
20160354137 | Fischell et al. | Dec 2016 | A1 |
20170332926 | Fischell | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
2384866 | Apr 2001 | CA |
2575458 | Mar 2006 | CA |
3151180 | Aug 1982 | DE |
0233100 | Aug 1987 | EP |
0497041 | Aug 1992 | EP |
0774991 | May 1997 | EP |
0811395 | Dec 1997 | EP |
1782852 | May 2007 | EP |
2092957 | Aug 2009 | EP |
2352542 | Aug 2011 | EP |
2429641 | Mar 2012 | EP |
2528649 | Dec 2012 | EP |
2656807 | Oct 2013 | EP |
2675458 | Dec 2013 | EP |
2694150 | Feb 2014 | EP |
2747688 | Jul 2014 | EP |
2885041 | Jun 2015 | EP |
2911735 | Sep 2015 | EP |
2914326 | Sep 2015 | EP |
3060148 | Aug 2016 | EP |
3132828 | Feb 2017 | EP |
3158866 | Apr 2017 | EP |
S499882 | Jan 1974 | JP |
62181225 | Aug 1987 | JP |
3041967 | Oct 1997 | JP |
2003510126 | Mar 2003 | JP |
2004016333 | Jan 2004 | JP |
WO-8501213 | Mar 1985 | WO |
WO-9104725 | Apr 1991 | WO |
WO-9220291 | Nov 1992 | WO |
WO-9302740 | Feb 1993 | WO |
WO-9307803 | Apr 1993 | WO |
WO-9400188 | Jan 1994 | WO |
WO-199407446 | Apr 1994 | WO |
WO-9411057 | May 1994 | WO |
WO-9525472 | Sep 1995 | WO |
WO-9531142 | Nov 1995 | WO |
WO-9533514 | Dec 1995 | WO |
WO-9600039 | Jan 1996 | WO |
WO-9604957 | Feb 1996 | WO |
WO-9611723 | Apr 1996 | WO |
WO-9703604 | Feb 1997 | WO |
WO-9713463 | Apr 1997 | WO |
WO-9713550 | Apr 1997 | WO |
WO-1997036548 | Oct 1997 | WO |
WO-9742990 | Nov 1997 | WO |
WO-9749453 | Dec 1997 | WO |
WO-9837926 | Sep 1998 | WO |
1998042403 | Oct 1998 | WO |
WO-9842403 | Oct 1998 | WO |
WO-9843700 | Oct 1998 | WO |
WO-9843701 | Oct 1998 | WO |
WO-9848888 | Nov 1998 | WO |
WO-199900060 | Jan 1999 | WO |
WO-1999002096 | Jan 1999 | WO |
WO-9933407 | Jul 1999 | WO |
WO-9951286 | Oct 1999 | WO |
WO-9952424 | Oct 1999 | WO |
WO-2000056237 | Sep 2000 | WO |
WO-0126729 | Apr 2001 | WO |
WO-2001022897 | Apr 2001 | WO |
WO-0170114 | Sep 2001 | WO |
WO-0209808 | Feb 2002 | WO |
WO-0226314 | Apr 2002 | WO |
WO-02053207 | Jul 2002 | WO |
WO-02058549 | Aug 2002 | WO |
WO-02070039 | Sep 2002 | WO |
WO-02070047 | Sep 2002 | WO |
WO-02085448 | Oct 2002 | WO |
WO-2002085192 | Oct 2002 | WO |
WO-03018108 | Mar 2003 | WO |
WO-03024311 | Mar 2003 | WO |
WO-2003022167 | Mar 2003 | WO |
WO-03028802 | Apr 2003 | WO |
WO-03063692 | Aug 2003 | WO |
WO-03071140 | Aug 2003 | WO |
WO-03076008 | Sep 2003 | WO |
WO-03082403 | Oct 2003 | WO |
WO-2003082080 | Oct 2003 | WO |
WO-2004011055 | Feb 2004 | WO |
WO-2004026370 | Apr 2004 | WO |
WO-2004026371 | Apr 2004 | WO |
WO-2004026374 | Apr 2004 | WO |
WO-2004028583 | Apr 2004 | WO |
WO-2004030718 | Apr 2004 | WO |
WO-2004032791 | Apr 2004 | WO |
WO-2004049976 | Jun 2004 | WO |
WO-2004107965 | Dec 2004 | WO |
WO-2005007000 | Jan 2005 | WO |
WO-2005014100 | Feb 2005 | WO |
WO-2005016165 | Feb 2005 | WO |
WO-05032646 | Apr 2005 | WO |
WO-2005032646 | Apr 2005 | WO |
WO-2005030072 | Apr 2005 | WO |
WO-2005041748 | May 2005 | WO |
WO-2005065284 | Jul 2005 | WO |
WO-2005084389 | Sep 2005 | WO |
WO-2005097256 | Oct 2005 | WO |
WO-2005110528 | Nov 2005 | WO |
WO-2005123183 | Dec 2005 | WO |
WO-2006007048 | Jan 2006 | WO |
WO-2006018528 | Feb 2006 | WO |
WO-2006022790 | Mar 2006 | WO |
WO-2006031899 | Mar 2006 | WO |
WO-2006041847 | Apr 2006 | WO |
WO-2006041881 | Apr 2006 | WO |
WO-2006105121 | Oct 2006 | WO |
WO-2007008954 | Jan 2007 | WO |
WO-2007035537 | Mar 2007 | WO |
WO-2007078997 | Jul 2007 | WO |
WO-2007086965 | Aug 2007 | WO |
WO-2007103879 | Sep 2007 | WO |
WO-2007103881 | Sep 2007 | WO |
WO-2007121309 | Oct 2007 | WO |
WO-2007146834 | Dec 2007 | WO |
WO-2008003058 | Jan 2008 | WO |
WO-2008049084 | Apr 2008 | WO |
WO-2008061150 | May 2008 | WO |
WO-2008061152 | May 2008 | WO |
WO-2008070413 | Jun 2008 | WO |
WO-2009088678 | Jul 2009 | WO |
WO-2010042653 | Apr 2010 | WO |
WO-2010078175 | Jul 2010 | WO |
WO-2011094367 | Aug 2011 | WO |
WO-2011133724 | Oct 2011 | WO |
WO-2012161875 | Nov 2012 | WO |
WO-2013028781 | Feb 2013 | WO |
WO-2013059735 | Apr 2013 | WO |
WO-2013063331 | May 2013 | WO |
WO-2013112844 | Aug 2013 | WO |
WO-2013169741 | Nov 2013 | WO |
WO-2013188689 | Dec 2013 | WO |
WO-2014031167 | Feb 2014 | WO |
WO-2014070820 | May 2014 | WO |
WO-2014070999 | May 2014 | WO |
WO-2014078301 | May 2014 | WO |
WO-2014189887 | Nov 2014 | WO |
Entry |
---|
European Search Report for European Application No. 13159256, dated Oct. 17, 2013, 6 pages. |
U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
“2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>. |
“2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
“Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
“Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
“Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
“Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news---latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
“Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
“Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
“Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
“Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
“The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
“The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
“Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
Asbell, Penny, “Conductive Keratoplasty for the Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=83002>. |
Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages. |
Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
Gertner, Jon, “Meet the Tech Duo That's Revitalizing the Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
Han, Y.-M, et al., “Renal artery embolization with diluted hot contrast medium: An experimental study.” J Vasc Interv Radiol, 12: 862-868 (2001). |
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
Imimdtanz, “Medtronic awarded industry's highest honour for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
Lee, S.J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
Lustgarten, D. L., et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>. |
Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
Sievert, Horst, “Novelty Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
Stouffer, G. A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
Swartz, J. F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
Avitall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 20 pages. |
Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2102378,00.html>. |
Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, Demarais et al. |
2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension, Guidelines Committee, Journal of Hypertension 2003, vol. 21, No. 6, pp. 1011-1053. |
Aars, H. And S. Akre, Reflex Changes in Sympathetic Activity and Arterial Blood Pressure Evoked by Afferent Stimulation of the Renal Nerve, Feb. 26, 1999, Acta physiol. Scand., vol. 78, 1970, pp. 184-188. |
Abramov, G.S. et al., Alteration in sensory nerve function following electrical shock, Burns vol. 22, No. 8, 1996 Elsevier Science Ltd., pp. 602-606. |
Achar, Suraj, M.D., and Suriti Kundu, M.D., Principles of Office Anesthesia: Part I. Infiltrative Anesthesia, Office Procedures, American Family Physician, Jul. 1, 2002, vol. 66, No. 1, pp. 91-94. |
Advanced Neuromodulation Systems' Comparison Chart, Dec. 16, 2008, pp. 1. |
Advances in the role of the sympathetic nervous system in cardiovascular medicine, 2001 SNS Report, No. 3, Springer, Published with an educational grant from Servier, pp. 1-8. |
Aggarwal, A. et al., Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension. 2003;41:553-7. |
Agnew, William F. et al., Evolution and Resolution of Stimulation-Induced Axonal Injury in Peripheral Nerve, May 21, 1999, Muscle & Nerve, vol. 22, Oct. 1999, John Wiley & Sons, Inc. 1999, pp. 1393-1402. |
Ahadian, Farshad M., M.D., Pulsed Radiofrequency Neurotomy: Advances in Pain Medicine, Current Pain and Headache Reports 2004, vol. 8, 2004 Current Science Inc., pp. 34-40. |
Alexander, B.T. et al., Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion, Hypertension, 2005; 45 (part 2): pp. 754-758. |
Alford, J. Winslow, M.D. and Paul D. Fadale, M.D., Evaluation of Postoperative Bupivacaine Infusion for Pain Management After Anterior Cruciate Ligament Reconstruction, The Journal of Arthroscopic and Related Surgery, vol. 19, No. 8, Oct. 2003 Arthroscopy Association of North America, pp. 855-861. |
Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
Amersham Health. Hypaque-Cysto, 2003, 6 pages. |
Andrews, B.T. et al., The use of surgical sympathectomy in the treatment of chronic renal pain. Br J Urol. 1997; 80: 6-10. |
Antman, Elliott M. and Eugene Braunwald, Chapter 37—Acute Myocardial Infarction, Heart Disease—A Textbook of Cardiovascular Medicine, 5th Edition, vol. 2, 1997, Edited by Eugene Braunwald, pp. 1184-1288. |
Archer, Steffen et al., Cell Reactions to Dielectrophoretic Manipulation, Mar. 1, 1999, Biochemical and Biophysical Research Communications, 1999 Academic Press, pp. 687-698. |
Arentz, T. et al., Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation. European Heart Journal. 2003. 24; pp. 963-969. |
Arias, M.D., Manuel J., Percutaneous Radio-Frequency Thermocoagulation with Low Temperature in the Treatment of Essential Glossopharyngeal Neuralgia, Surg. Neurol. 1986, vol. 25, 1986 Elsevier Science Publishing Co., Inc., pp. 94-96. |
Aronofsky, David H., D.D.S., Reduction of dental postsurgical symptoms using nonthermal pulsed high-peak-power electromagnetic energy, Oral Surg., Nov. 1971, vol. 32, No. 5, pp. 688-696. |
Aspelin, Peter, M.D., Ph.D. et al., Nephrotoxic Effects in High-Risk Patients Undergoing Angiography, Feb. 6, 2003, New England Journal of Medicine 2003, vol. 348, No. 6, 2003 Massachusetts Medical Society, pp. 491-499. |
Atrial Fibrillation Heart and Vascular Health on Yahoo! Health. 2 pgs. <URL: http://health.yahoo.com/topic/heart/overview/article/healthwise/hw160872;_ylt=AiBT43Ey74HQ7ft3jAb4C.sPu7cF> Feb. 21, 2006. |
Augustyniak, Robert A. et al., Sympathetic Overactivity as a Cause of Hypertension in Chronic Renal Failure, Aug. 14, 2001, Journal of Hypertension 2002, vol. 20, 2002 Lippincott Williams & Wilkins, pp. 3-9. |
Awwad, Ziad M., FRCS and Bashir A. Atiyat, GBA, JBA, Pain relief using continuous bupivacaine infusion in the paravertebral space after loin incision, May 15, 2004, Saudi Med J 2004, vol. 25 (10), pp. 1369-1373. |
Badyal, D. K., H. Lata and A.P. Dadhich, Animal Models of Hypertension and Effect of Drugs, Aug. 19, 2003, Indian Journal of Pharmacology 2003, vol. 35, pp. 349-362. |
Baker, Carol E. et al., Effect of pH of Bupivacaine on Duration of Repeated Sciatic Nerve Blocks in the Albino Rat, Anesth Analg, 1991, vol. 72, The International Anesthesia Research Society 1991, pp. 773-778. |
Balazs, Tibor, Development of Tissue Resistance to Toxic Effects of Chemicals, Jan. 26, 1974, Toxicology, 2 (1974), Elsevier/North-Holland, Amsterdam, pp. 247-255. |
Barajas, L. Innervation of the renal cortex. Fex Proc. 1978;37:1192-201. |
Barrett, Carolyn J. et al., Long-term control of renal blood flow: what is the role of the renal nerves?, Jan. 4, 2001, Am J Physiol Regulatory Integrative Comp Physiol 280, 2001, the American Physiological Society 2001, pp. R1534-R1545. |
Barrett, Carolyn J. et al., What Sets the Long-Term Level of Renal Sympathetic Nerve Activity, May 12, 2003, Integrative Physiology, Circ Res. 2003, vol. 92, 2003 American Heart Association, pp. 1330-1336. |
Bassett, C. Andrew L. et al., Augmentation of Bone Repair by Inductively Coupled Electromagnetic Fields, May 3, 1974, Science, vol. 184, pp. 575-577. |
Bassett, C. Andrew L., Fundamental and Practical Aspects of Therapeutic Uses of Pulsed Electromagnetic Fields (PEMFs), Critical Reviews in Biomedical Engineering, vol. 17, Issue 5, 1989, pp. 451-514. |
Beebe, Stephen J. et al., Nanosecond pulsed electric fields modulate cell function through intracellular signal transduction mechanisms, Apr. 8, 2004, Physiol. Meas. 25, 2004, IOP Publishing Ltd. 2004, pp. 1077-1093. |
Beebe, Stephen J., et al., Nanosecond Pulsed Electric Field (nsPEF) Effects on Cells and Tissues: Apoptosis Induction and Tumor Growth Inhibition, Oct. 11, 2001, IEEE Transactions on Plasma Science, vol. 30, No. 1, Feb. 2002, IEEE 2002, pp. 286-292. |
Bello-Reuss, E. et al., Acute unilateral renal denervation in rats with extracellular volume expansion, Departments of Medicine and Physiology, University of North Carolina School of Medicine. F26-F32 Jul. 1975. |
Bello-Reuss, E. et al., Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption, J Clin Invest, 1976;57:1104-1107. |
Bello-Reuss, E. et al., Effects of Acute Unilateral Renal Denervation in the Rat, J Clin Invest, 1975;56:208-217. |
Berde, C. et al., Local Anesthetics, Anesthesia, Chapter 13, 5th addition, Churchill-Livingston, Philadelphia 2000, pp. 491-521. |
Bhadra, Niloy and Kevin L. Kilgore, Direct Current Electrical Conduction Block of Peripheral Nerve, Feb. 25, 2004, IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol. 12, No. 3, Sep. 2004, pp. 313-324. |
Bhandari, A. and Ellias, M., Loin pain hematuria syndrome: Pain control with RFA to the Splanchanic plexus, The Pain Clinic, 2000, vol. 12, No. 4, pp. 323-327. |
Bhatt, Deepak L. et al., Rhabdomyolysis Due to Pulsed Electric Fields, May 11, 1989, Plastic and Reconstructive Surgery Jul. 1990, pp. 1-11. |
Bichet, D., et al., Renal intracortical blood flow and renin secretion after denervation by 6-hydroxydopamine. Can J Physiol Pharmacol. 1982;60:184-92. |
Bigler, D. et al., Tachyphylaxis during postoperative epidural analgesia—new insights, Apr. 15, 1987, Letter to the Editor, Acta Anaesthesiol Scand. 1987, vol. 31, pp. 664-665. |
Binder, Allan et al., Pulsed Electromagnetic Field Therapy of Persistent Rotator Cuff Tendinitis, The Lancet, Saturday Mar. 31, 1984, The Lancet Ltd., pp. 695-698. |
Black, M.D., Henry R., Resistant Hypertension 2004, presentation at Rush University Medical Center, Jul. 15, 2004, 40 pages. |
Blad, B., et al., An Electrical Impedance index to Assess Electroporation in Tissue, Tissue and Organ (Therapy), 2001, Oslo, www.bl.uk <http://www.bl.uk> British Library, pp. 31-34. |
Blair, M. L. et al, Sympathetic activation cannot fully account for increased plasma renin levels during water deprivation, Sep. 23, 1996, Am. J. Physiol., vol. 272, 1997, the American Physiological Society 1997, pp. R1197-R1203. |
Blomberg, S.G., M.D., PhD, Long-Term Home Self-Treatment with High Thoracic Epidural Anesthesia in Patients with Severe Coronary Artery Disease, Mar. 29, 1994, Anesth Analg 1994, vol. 79, 1994 International Anesthesia Research Society, pp. 413-421. |
Boehmer, J.P., Resynchronization Therapy for Chronic CHF: Indications, Devices and Outcomes. Penn State College of Medicine: Penn State Heart and Vascular Institute. Transcatheter Cardiovascular Therapeutics 2005, 31 slides. |
Bourge, R.C., Heart Failure Monitoring Devices: Rationale and Status 28 pages, Feb. 2001. |
Braunwald, E., Heart Disease, A Textbook of Cardiovascular Medicine, 5th Ed., vol. 2, 1997, pp. 480-481, 824-825, 1184-1288 and 1923-1925, W.B. Saunders Company. |
Bravo, E.L., et al., Renal denervation for resistant hypertension, American Journal of Kidney Diseases, 2009, 3 pgs. |
Bunch, Jared T. et al. Mechanisms of Phrenic Nerve Injury During Radiofrequency Ablation at the Pulmonary Vein Orifice. Journal of Cardiovascular Electrophysiclody. vol. 16, No. 12. pp. 1318-1325. Dec. 2005. |
Burkhoff, D., Interventional Device-Based Therapy for CHF Will Redefine Current Treatment Paradigms. Columbia University. 2004. 32 slides. |
Burns, J. et al., Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115:1999-2005. |
Cahana, A. et al., Acute Differential Modulation of Synaptic Transmission and Cell Survival During Exposure to Pulsed and Continuous Radiofrequency Energy, May 2003, The Journal of Pain, vol. 4, No. 4, © 2003 by the American Pain Society, pp. 197-202. |
Cahana, Alex, M.D., Pulsed Radiofrequency: A Neurobiologic and Clinical Reality, May 17, 2005, Anesthesiology 2005, vol. 103, No. 6, Dec. 2005, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., p. 1311. |
Calaresu, F.R. et al., Haemodynamic Responses and Renin Release During Stimulation of Afferent Renal Nerves in the Cat, Aug. 12, 1975, J. Physiol. 1976, vol. 255, pp. 687-700. |
Cameron, Tracy. Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs. IEEE Transactions on Biomedical Engineering, vol. 44, No. 9, Sep. 1997. pp. 781-790. |
Campese, V.M. et al., Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878-82. |
Campese, V.M. et al., Renal Afferent Denervation Prevents the Progression of Renal Disease in the Renal Ablation Model of Chronic Renal Failure in the Rat, Am J Kidney Dis. 1995;26:861-5. |
Campese, V.M., A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications, Clin Exp Nephrol (2003) 7: 167-171, Japanese Society of Nephrology 2003. |
Campese, V.M., Neurogenic factors and hypertension in chronic renal failure, Journal of Nephrology, vol. 10, No. 4, 1997, Societa Italiana di Nefrologia, pp. 184-187. |
Campese, V.M., Neurogenic factors and hypertension in renal disease. Kidney Int. 2000;57 Suppl 75:S2-3. |
Canbaz, S. et al., Electrophysiological evaluation of phrenic nerve injury during cardiac surgery—a prospective, controlled clinical study. BioMed Central. 5 pgs. 2004. |
Cardiac Glycosides, Heart Disease—A Textbook of Cardiovascular Medicine vol. 2, Edited by Eugene Braunwald, 5th Edition, 1997 WB Saunders Company, pp. 480-481. |
Carls, G. et al., Electrical and magnetic stimulation of the intercostal nerves: a comparative study, Electromyogr, clin. Neurophysiol. 1997, vol. 37, pp. 509-512. |
Carlson, Scott H. and J. Michael Wyss, e-Hypertension—Opening New Vistas, Introductory Commentary, Hypertension 2000, vol. 35, American Heart Association, Inc. 2000, p. 538. |
Carson, P., Device-based Treatment for Chronic Heart Failure: Electrical Modulation of Myocardial Contractility. Transcatheter Cardiovascular Therapeutics 2005, 21 slides. |
Chang, Donald C., Cell poration and cell fusion using an oscillating electric field, Biophysical Journal, vol. 56, Oct. 1989, Biophysical Society, pp. 641-652. |
Chen, S.A. et al., Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablataion, Circulation, 1999, 100:1879-1886. |
Chin, J.L. et al., Renal autotransplantation for the loin pain-hematuria syndrome: long term follow up of 26 cases, J Urol, 1998, vol. 160, pp. 1232-1236. |
Chiou, C.W. et al., Efferent Vagal Innervation of the Canine Atria and Sinus and Atrioventricular Nodes. Circulation. Jun. 1997. 95(11):2573-2584. Abstract only. 2 pgs. |
Chobanian, Aram V. et al., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Nov. 6, 2003, Hypertension 2003, vol. 42, 2003 American Heart Association, Inc., pp. 1206-1252. |
Clinical Trials in Hypertension and Renal Diseases, Slide Source, www.hypertensiononline.org, 33 pages Aug. 13, 2001. |
Conradi, E. and Ines Helen Pages, Effects of Continous and Pulsed Microwave Irradiation on Distribution of Heat in the Gluteal Region of Minipigs, Scand J Rehab Med, vol. 21, 1989, pp. 59-62. |
Converse, R.L., Jr. et al., Sympathetic Overactivity in Patients with Chronic Renal Failure, N Engl J Med. Dec. 31, 1992, vol. 327 (27), pp. 1912-1918. |
Cosman, E.R., Jr. et al., Electric and Thermal Field Effects in Tissue Around Radiofrequency Electrodes, Pain Medicine, vol. 6, No. 6, 2005, American Academy of Pain Medicine, pp. 405-424. |
Cosman, E.R., Ph.D., A Comment on the History of the Pulsed Radiofrequency Technique for Pain Therapy, Anesthesiology Dec. 2005, vol. 103, No. 6, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., p. 1312. |
Crawford, William H. et al., Pulsed Radio Frequency Therapy of Experimentally Induced Arthritis in Ponies, Dec. 18, 1989, Can. J. Vet. Res. 1991, vol. 55, pp. 76-85. |
Curtis, J.J. et al., Surgical theray for persistent hypertension after renal transplantation, Transplantation, 1981, 31(2):125-128. |
Dahm, Peter et al., Efficacy and Technical Complications of Long-Term Continuous Intraspinal Infusions of Opioid and/or Bupivacaine in Refractory Nonmalignant Pain . . . , Oct. 6, 1997, The Clinical Journal of Pain, vol. 14, No. 1, 1998, Lippincott-Raven Publishers 1998, pp. 4-16. |
Dahm, Peter O. et al., Long-Term Intrathecal Infusion of Opioid and/or Bupivacaine in the Prophylaxis and Treatment of Phantom Limb Pain, Neuromodulation, vol. 1, No. 3, 1998, International Neuromodulation Society 1998, pp. 111-128. |
Dang, Nicholas C. et al., A Novel Approach to Increase Total Urine Output in Heart Failure: Renal Nerve Blockade, ACC 2005 poster; 1 page. |
Daniel, Alan and Honig, Carl R. Does Histamine Influence Vasodilation Caused by Prolonged Arterial Occlusion or Heavy Exercise? The Journal of Pharmacology and Experimental Therapeutics. vol. 215 No. 2. Aug. 21, 1980. pp. 533-538. |
Davalos, R. et al., Electrical Impedance Tomography for Imaging Tissue Electroporation, Jul. 25, 2003, IEEE Transactions on Biomedical Engineering, vol. 51, No. 5, May 2004, IEEE 2004, pp. 761-767. |
Davalos, R.V. et al., Tissue Ablation with Irreversible Electroporation, Sep. 7, 2004, Annals of Biomedical Engineering, Feb. 2005, vol. 33, No. 2, 2005 Biomedical Engineering Society, pp. 223-231. |
De Leeuw, Peter W. et al., Renal Vascular Tachyphylaxis to Angiotensin II: Specificity of the Response for Angiotensin, Dec. 28, 1981, Life Sciences, vol. 30, 1982 Pergamon Press Ltd., pp. 813-819. |
Deng, Jingdong et al., The Effects of Intense Submicrosecond Electrical Pulses on Cells, Nov. 26, 2002, Biophysical Journal, vol. 84, Apr. 2003, Biophysical Society 2003, pp. 2709-2714. |
Denton, Kate M. et al., Differential Neural Control of Glomerular Ultrafiltration, Jan. 30, 2004, Proceedings of the Australian Physiological and Pharmacological Society Symposium: Hormonal, Metabolic and Neural Control of the Kidney, Clinical and Experimental Pharmacology and Physiology (2004) 31, pp. 380-386. |
Dev, Nagendu B., Ph.D. et al., Intravascular Electroporation Markedly Attenuates Neointima Formation After Balloon Injury of the Carotid Artery in the Rat, Journal of Interventional Cardiology, vol. 13, No. 5, 2000, pp. 331-338. |
Dev, Nagendu B., Ph.D. et al., Sustained Local Delivery of Heparin to the Rabbit Arterial Wall with an Electroporation Catheter, May 5, 1998, Catheterization and Cardiovascular Diagnosis, vol. 45, 1998, Wiley-Liss, Inc. 1998, pp. 337-345. |
Devereaux, R.B. et al., Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial, Circulation, 2004, vol. 110, pp. 1456-1462. |
DiBona, Gerald F. and Linda L. Sawin, Role of renal nerves in sodium retention of cirrhosis and congestive heart failure, Sep. 27, 1990, Am. J. Physiol. 1991, vol. 260, 1991 the American Physiological Society, pp. R298-R305. |
DiBona, Gerald F. and Susan Y. Jones, Dynamic Analysis of Renal Nerve Activity Responses to Baroreceptor Denervation in Hypertensive Rats, Sep. 19, 2000, Hypertension Apr. 2001, American Heart Association, Inc. 2001, pp. 1153-1163. |
DiBona, Gerald F. and Ulla C. Kopp, Neural Control of Renal Function, Physiological Reviews, vol. 77, No. 1, Jan. 1997, the American Physiological Society 1997, pp. 75-197. |
DiBona, Gerald F. and Ulla C. Kopp, Role of the Renal Sympathetic Nerves in Pathophysiological States, Neural Control of Renal Function, vol. 77, pp. 142-197 Jan. 1997. |
DiBona, Gerald F., Functionally Specific Renal Sympathetic Nerve Fibers: Role in Cardiovascular Regulation, Mar. 6, 2001, American Journal of Hypertension, 2001, vol. 14, 2001 American Journal of Hypertension, Ltd. Published by Elsevier Science Inc., pp. 163S-170S. |
DiBona, Gerald F., L.L. Sawin, Effect of renal nerve stimulation on NaCl and H2O transport in Henle's loop of the rat,: 1982, American Physiological Society, F576-F580, 5 pgs. |
DiBona, Gerald F., Nervous Kidney—Interaction Between Renal Sympathetic Nerves and the Renin-Angiotensin System in the Control of Renal Function, Jun. 21, 2000, Hypertension 2000, vol. 36, 2000 American Heart Association, Inc., pp. 1083-1088. |
DiBona, Gerald F., Neural Control of the Kidney—Past, Present and Future, Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
DiBona, Gerald F., Neural Control of the Kidney: Functionally Specific Renal Sympathetic Nerve Fibers, Starling Lecture, Am J Physiol Regulatory Integrative Comp Physiol, 2000, 279, 2000 The American Physiological Society, pp. R1517-R1524. |
DiBona, Gerald F., Peripheral and Central Interactions between the Renin-Angiotensin System and the Renal Sympathetic Nerves in Control of Renal Function, Annals New York Academy of Sciences, pp. 395-406 Jan. 25, 2006. |
DiBona, Gerald F., Renal Innervation and Denervation: Lessons from Renal Transplantation Reconsidered, Artificial Organs, vol. 11, No. 6, Raven Press, Ltd., 1987 International Society for Artificial Organs, pp. 457-462. |
DiBona, Gerald F., Sympathetic Nervous System and the Kidney in Hypertension, Current Opinion in Nephrology and Hypertension 2002, vol. 11, 2002 Lippincott Williams & Wilkins, pp. 197-200. |
DiBona, Gerald F., The Sympathetic Nervous System and Hypertension, Dec. 4, 2003, Hypertension Highlights, Hypertension Feb. 2004, vol. 43, 2004 American Heart Association, Inc., pp. 147-150. |
DiBona, Gerald, LL Sawin, Effect of renal denervation on dynamic autoregulation of renal blood flow, Feb. 12, 2004, AmJ Physiol Renal Physiol 286, pp. F1209-F1218. |
Dong, Jun et al. Incidence and Predictors of Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation Using the Anatomic Pulmonary Vein Ablation Approach: Results from Paired Magnetic Resonance Imaging. Journal of Cardiovascular Electrophysiology. vol. 16, No. 8, Aug. 2005. pp. 845-852. |
Dorros, Gerald, M.D., Renal Artery Stenting State of the Art, presentation, TCT, Washington D.C., Sep. 2003, 27 pages. |
Dueck, Ron, M.D., Noninvasive Cardiac Output Monitoring, The Cardiopulmonary and Critical Care Journal, Chest, vol. 120, sec. 2, Aug. 2001, American College of Chest Physicians 2005, pp. 339-341, 5 pages. |
Dunn, Matthew D. et al., Laparoscopic Nephrectomy in Patients With End-Stage Renal Disease and Autosomal Dominant Polycystic Kidney Disease,Oct. 25, 1999, American Journal of Kidney Diseases, vol. 35, No. 4 Apr. 2000, National Kidney Foundation, Inc. 2000, pp. 720-725. |
Durand, D.M., Electric Field Effects in Hyperexcitable Neural Tissue: A Review, Radiation Protection Dosimetry, vol. 106, No. 4, 2003 Nuclear Technology Publishing, pp. 325-331. |
Effects of Renal Failure on the Cardiovascular System, 5th Edition Heart Disease, A Textbook of Cardiovascular Medicine, vol. 2, Edited by Eugene Braunwald, 1997, W.B. Saunders Company, pp. 1923-1925. |
Electrical Stimulation for the Treatment of Chronic Wounds, Radiation Protection Standard, Maximum Exposure Levels to Radiofrequency Fields—3 KHz to 300 GHz, Radiation Protection Series No. 3, Australian Radiation Protection and Nuclear Safety Agency, Apr. 1996, 322 pgs. |
Electropermeabilization (Electroporation), Cyto Pulse Sciences, Inc., http://www.cytopulse.com/electroporation.html (last accessed Mar. 3, 2005), 3 pgs. |
Electroporation based Technologies and Treatments, ESPE Newsletter No. 6, QLK 02002-2003, Jan. 2005, www.cliniporator.com, 4 pgs. |
End-stage renal disease payment policies in traditional Medicare, Chapter 8, Report to the Congress: Medicare Payment Policy, Mar. 2001, Medpac, pp. 123-138. |
Epidemiology of Renal Disease in Hypertension, slide presentation by hypertensiononline.org, 21 pages. Mar. 30, 2001. |
Erdine, Serap and Alev Arat-Ozkan, Resistant Hypertension, European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2003, vol. 4, No. 15, 2 pages. |
Esler, M. et al., Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8:S39-43. |
Esler, M. et al., Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens. 1989; 2:140S-146S. |
Esler, M. et al., Sympathetic nerve biology in essential hypertension, Clin and Exp Pharmacology and Physiology, 2001, 28:986-989. |
European Examination Report; European Patent Application No. 07799148.7; Applicant: Ardian, Inc.; dated Jan. 19, 2010, 4 pgs. |
European Examination Report; European Patent Application No. 09156661.2; Applicant: Ardian, Inc.; dated Jan. 19, 2010, 6 pgs. |
European Search Report; European Patent Application No. 05806045.0; Applicant: Ardian, Inc.; dated Sep. 22, 2009, 8 pgs. |
European Search Report; European Patent Application No. 05811851.4; Applicant: Ardian, Inc.; dated Oct. 1, 2009, 7 pgs. |
European Search Report; European Patent Application No. 06847926.0; Applicant: Ardian, Inc.; dated Feb. 10, 2010, 6 pgs. |
European Search Report; European Patent Application No. 07757925.8; Applicant: Ardian, Inc.; dated Apr. 29, 2010, 9 pgs. |
European Search Report; European Patent Application No. 07798341.9; Applicant: Ardian, Inc.; dated Aug. 4, 2011; 6 pgs. |
European Search Report; European Patent Application No. 07799148.7; Applicant: Ardian, Inc.; dated Jul. 23, 2009, 6 pgs. |
European Search Report; European Patent Application No. 07868755.5; Applicant: Ardian, Inc.; dated Jul. 28, 2010, 7 pgs. |
European Search Report; European Patent Application No. 09156661.2; Applicant: Ardian, Inc.; dated Jul. 23, 2009, 6 pgs. |
European Search Report; European Patent Application No. 09167937.3; Applicant: Ardian, Inc.; dated Nov. 11, 2009, 6 pgs. |
European Search Report; European Patent Application No. 09168202.1; Applicant: Ardian, Inc.; dated Nov. 11, 2009, 5 pgs. |
European Search Report; European Patent Application No. 09168204.7; Applicant: Ardian, Inc.; dated Nov. 19, 2009, 6 pgs. |
Evelyn, K.A. et al., Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension, Am J Med, 1960;28:188-221. |
Ex parte Quayle Office Action; U.S. Appl. No. 11/144,173; dated May 28, 2009, 4 pgs. |
Fact Book Fiscal Year 2003, National Institutes of Health National Heart, Lung, and Blood Institute, Feb. 2004, 197 pgs. |
Fajardo, J. et al., Effect of chemical sympathectomy on renal hydroelectrolytic handling in dogs with chronic caval constriction. Clin Physiol Biochem. 1986;4:252-6. |
Fareed, Jawed, Ph.D. et al., Some Objective Considerations for the Use of Heparins and Recombinant Hirudin in Percutaneous Transluminal Coronary Angoplasty, Seminars in Thrombosis and Hemostasis 1991, vol. 17, No. 4, 1991 by Thieme Medical Publishers, Inc., pp. 455-470. |
Ferguson, D.R. et al., Responses of the pig isolated renal artery to transmural electrical stimulation and drugs, Dec. 7, 1984, Br. J. Pharmac. 1985, vol. 84, The Macmillan Press Ltd. 1985, pp. 879-882. |
Fernandez-Ortiz, Antonio, et al., A New Approach for Local Intravascular Drug Delivery—Iontophoretic Balloon, Intravascular Iontophoretic Local Delivery, Circulation, vol. 89, No. 4, Apr. 1994, pp. 1518-1522. |
Fields, Larry E. et al., The Burden of Adult Hypertension in the United States 1999 to 2000—A Rising Tide, May 18, 2004, American Heart Association 2004, Hypertension Oct. 2004, pp. 1-7. |
Final Office Action; U.S. Appl. No. 11/233,814; dated Jan. 29, 2009, 11 pgs. |
Final Office Action; U.S. Appl. No. 11/266,993; dated Jan. 8, 2010, 7 pgs. |
Final Office Action; U.S. Appl. No. 11/363,867; dated May 1, 2009, 8 pgs. |
Final Office Action; U.S. Appl. No. 11/451,728; dated Jan. 13, 2009, 7 pgs. |
Final Office Action; U.S. Appl. No. 11/599,649; dated Jan. 15, 2009, 10 pgs. |
Final Office Action; U.S. Appl. No. 11/599,723; dated Apr. 5, 2010, 17 pgs. |
Final Office Action; U.S. Appl. No. 11/599,890; dated Apr. 29, 2009, 9 pgs. |
Fischell, Tim A. et al., Ultrasonic Energy: Effects on Vascular Function and Integrity, Circulation: Journal of the American Heart Association. 1991. 84;pp. 1783-1795. |
Freeman, Scott A. et al., Theory of Electroporation of Planar Bilayer Membranes: Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation, Feb. 23, 1994, Biophysical Journal, Jul. 1994, vol. 67, 1994 by the Biophysical Society, pp. 42-56. |
Fukuoka, Yuko et al., Imaging of neural conduction block by neuromagnetic recording, Oct. 16, 2002, Clinical Neurophysiology, vol. 113, 2002, Elsevier Science Ireland Ltd. 2002, pp. 1985-1992. |
Fuster, Valentin et al. ACC/AHA/ESC Practice Guidelines: ACA/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. JACC vol. 48, No. 4, Aug. 15, 2006. |
Gami, Apoor S., M.D. and Vesna D. Garovic, M.D., Contrast Nephropathy After Coronary Angiography, Mayo Clin Proc. 2004, vol. 79, 2004 Mayo Foundation for Medical Education and Research, pp. 211-219. |
Gattone II, Vincent H. et al., Contribution of Renal Innervation to Hypertension in Polycystic Kidney Disease in the Rat, University of Chicago Section of Urology, 16 pages, Mar. 17, 2008. |
Gaylor, D.C. et al., Significance of Cell Size and Tissue Structure in Electrical Trauma, Jan. 26, 1988, J. theor. Biol. 1988, vol. 133, 1988 Academic Press Limited, pp. 223-237. |
Gazdar, A.F. and G.J. Dammin, Neural degeneration and regeneration in human renal transplants, NEJM, Jul. 30, 1970, 283:222-244. |
Gehl, Julie et al., In Vivo Electroporation of Skeletal Muscle: Threshold, Efficacy and Relation to Electric Field Distribution, Biochimica et Biophysica Acta, 1428, 1999, Elsevier Science B.V. 1999, pp. 233-240, www.elsevier.com/locate/bba <http:www.elsevier.com/locate/bba>. |
Getts, R.T. et al., Regression of left ventricular hypertrophy after bilateral nephrectomy, Nephrol Dial Transplant, 2006, vol. 21, pp. 1089-1091. |
Ghoname, El-sayed A. et al., Percutaneous electrical nerve stimulation: an alternative to TENS in the management of sciatica, Apr. 26, 1999, Pain 1999, vol. 83, 1999 International Association for the Study of Pain / Published by Elsevier Science B.V., pp. 193-199. |
Gimple, M.D., Lawrence et al., Effect of Chronic Subcutaneous or Intramural Administration of Heparin on Femoral Artery Restenosis After Balloon Angioplasty in Hypercholesterolemic Rabbits, Laboratory Investigation, Circulation, vol. 86, No. 5, Nov. 1992, pp. 1536-1546. |
Goldberger, Jeffrey J. et al., New technique for vagal nerve stimulation, Jun. 2, 1999, Journal of Neuroscience Methods 91, 1999, Elsevier Science B.V. 1999, pp. 109-114. |
Gorbunov, F.E. et al., The Use of Pulsed and Continuous Short Wave Diathermy (Electric Field) in Medical Rehabilitation of the Patients with Guillan-Barre Syndrome and Other Peripheral Myelinopathies, May 6, 1994, 5 pages (most of article in Russian language). |
Gottschalk, C.W., Renal nerves and sodium excretion, Ann. Rev. Physiol., 1979, 41:229-240. |
Greenwell, T.J. et al., The outcome of renal denervation for managing loin pain haematuria syndrome. BJU International, 2004; 4 pgs. |
Gruberg, Luis, M.D. et al., The Prognostic Implications of Further Renal Function Deterioration Within 48 h of Interventional Coronary Procedures in Patients with Pre-existent Chronic Renal Insufficiency, Jun. 19, 2000, Journal of the American College of Cardiology 2000, vol. 36, No. 5, 2000 by the American College of Cardiology, pp. 1542-1548. |
Guimaraes, Sarfim. Vascular Adrenoceptors: An Update. pp. 319-356, Jun. 1, 2001. |
Haissaguerre, M. et al., Spontaneous initiation of atrial fibrillation by ectopic beats orginating in the pulmonary veins, New England Journal of Medicine, 1998, 339: 659-666. |
Hajjar, Ihab, M.D., M.S. and Theodore A. Kotchen, M.D., Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000, JAMA, Jul. 9, 2003, vol. 290, No. 2, pp. 199-206. |
Hammer, Leah W. Differential Inhibition of Functional Dilation of Small Arterioles by Indomethacin and Glibenclamide. Hypertension. Feb. 2001 Part II. pp. 599-603. |
Hampers, C.L. et al., A hemodynamic evaluation of bilateral nephrectomy and hemodialysis in hypertensive man, Circulation. 1967;35:272-288. |
Hamza, M.D., Mohamed A. et al., Effect of the Duration of Electrical Stimulation on the Analgesic Response in Patients with Low Back Pain, Anesthesiology, vol. 91, No. 6, Dec. 1999, American Society of Anesthesiologists, Inc. 1999, pp. 1622-1627. |
Han, Hyo-Kyung and Gordon L. Amidon, Targeted Prodrug Design to Optimize Drug Delivery, Mar. 21, 2000, AAPS Pharmsci 2000, 2 (1) article 6, pp. 1-11. |
Hansen, J.M. et al., The transplanted human kidney does not achieve functional reinnervation, Clin Science, 1994, vol. 87, pp. 13-20. |
Hasking, G.J. et al., Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-21. |
Hausberg, M. et al., Sympathetic nerve activity in end-stage renal disease, Circulation, 2002, 106: 1974-1979. |
Heart Arrhythmia Heart and Vascular Health on Yahoo! Health. 13 pgs. <URL: http://health.yahoo.com/topic/heart/overview/article/mayoclinic/21BBE2B0-128D-4AA2-A5CE215065586678;_ylt=Aqd9M5rNyHD0sbPOmHXFhLcPu7cF> Feb. 16, 2005. |
Heart Disease and Stroke Statistics—2004 Update, American Heart Association, American Stroke Association, Dallas, Texas, 2003 American Heart Association, 52 pgs. |
Heida, Tjitske, et al., Investigating Membrane Breakdown of Neuronal Cells Exposed to Nonuniform Electric Fields by Finite-Element Modeling and Experiments, May 9, 2002, IEEE Transactions on Biomedical Engineering, vol. 49, No. 10, Oct. 2002, IEEE 2002, pp. 1195-1203. |
Heuer, G.J., The surgical treatment of essential hypertension, Annals of Surgery, 1936; 104 (4): 771-786. |
Higuchi, Yoshinori, M.D., Ph.D. et al, Exposure of the Dorsal Root Ganglion in Rats to Pulsed Radiofrequency Currents Activates Dorsal Horn Lamina I and II Neurons, Dec. 4, 2001, Experimental Studies, Neurosurgery, vol. 50, No. 4, Apr. 2002, pp. 850-856. |
Hildebrand, Keith R., D.V.M., Ph.D. et al., Stability, Compatibility, and Safety of Intrathecal Bupivacaine Administered Chronically via an Implantable Delivery System, May 18, 2001, The Clinical Journal of Pain, vol. 17, No. 3, 2001 Lippincott Williams & Wilkins, Inc., pp. 239-244. |
Hing, Esther, M.P.H. and Kimberly Middleton, B.S.N., M.P.H., National Hospital Ambulatory Medical Care Survey: 2001 Outpatient Department Summary, Aug. 5, 2003, Advance Data from Vital and Health Statistics, No. 338, CDC, 32 pages. |
Hodgkin, Douglas D. et al., Electrophysiologic Characteristics of a Pulsed Iontophoretic Drug-Delivery System in Coronary Arteries, Journal of Cardiovascular Pharmacology. 29(1):pp. 39-44, Jan. 1997, Abstract, 2 pgs. |
Hopp, F.A. et al., Respiratory Responses to Selective Blockade of Carotid Sinus Baroreceptors in the Dog, Jun. 22, 2005, Am J Physiol Regul Integr Comp Physiol 1998, vol. 275, 2005 American Physiological Society, pp. R10-R18. |
Hortobagyi, Gabriel N., Randomized Trial of High-Dose Chemotherapy and Blood Cell Autographs for High-Risk Primary Breast Carcinoma, Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000, pp. 225-233. |
Horwich, Tamara, M.D., New Advances in the Diagnosis and Management of Acute Decompensated Heart Failure, the heart.org satellite program, Rapid Review, CME Symposium presented on Nov. 8, 2004 at the Sheraton New Orleans Hotel, 4 pages. |
Huang, Wann-Chu et al. Renal Denervation Prevents and Reverses Hyperinsulinemia-Induced Hypertension in Rats, Mar. 25, 1998, Hypertension 1998, vol. 32, 1998 American Heart Association, pp. 249-254. |
Huang, Yifei et al., Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural and cellular responses, Jan. 8, 2004, Am J Physiol. Heart Circ. Physiol. 2004, vol. 286, 2004 the American Physiological Society, pp. H2141-H2150. |
Hughes, Gordon B., M.D. et al., A Comparative Study of Neuropathologic Changes Following Pulsed and Direct Current Stimulation of the Mouse Sciatic Nerve, Jun. 27, 1980, American Journal of Otolaryngology, Nov. 1980, vol. 1, No. 5, pp. 378-384. |
Hypertension and Renal Disease: Mechanisms, Slide Show by www.hypertensiononline.org, 22 pages Mar. 30, 2001. |
Hypertension Incidence and Prevalence, Age-Specific Rates, by Gender, B.C., 2001/2002, Graph, Chronic Disease Management, May 2003, British Columbia Ministry of Health Services, 1 page. |
Implantable Neurostimulation Systems, Medtronic Neurological, Jan. 18, 1999, 6 pages. http://medtronic.com/neuro/paintherapies/pain_treatment_ladder/pdf/implantable_brochure.pdf. |
Implantable Pump—The Medtronic MiniMed 2007 Implantable Insulin Pump System, Medtronic MiniMed 2004, 4 pgs. |
International Search Report and Written Opinion for PCT/US2009/069334; Applicant: Ardian, Inc.; dated Mar. 1, 2010, 10 pgs. |
International Search Report and Written Opinion, PCT/US05/35693, dated Mar. 8, 2006, Applicant: Ardian, Inc., 29 pgs. |
International Search Report and Written Opinion, PCT/US05/35757, dated Dec. 27, 2006, Applicant: Ardian, Inc., 8 pgs. |
International Search Report and Written Opinion, PCT/US06/36120, dated Jun. 25, 2008, Applicant: Ardian, Inc., 10 pgs. |
International Search Report and Written Opinion, PCT/US06/41889, dated Oct. 20, 2008, Applicant: Ardian, Inc., 7 pgs. |
International Search Report and Written Opinion, PCT/US06/48822, dated Aug. 15, 2008, Applicant: Ardian, Inc., 12 pgs. |
International Search Report and Written Opinion, PCT/US07/633222, dated Mar. 3, 2008, Applicant: Ardian, Inc., 10 pgs. |
International Search Report and Written Opinion, PCT/US07/63324, dated Oct. 10, 2008, Applicant: Ardian, Inc., 10 pgs. |
International Search Report and Written Opinion, PCT/US07/66539, dated Jan. 28, 2008, Applicant: Ardian, Inc., 6 pgs. |
International Search Report and Written Opinion, PCT/US07/70799, dated Jul. 2, 2008, Applicant: Ardian, Inc., 7 pgs. |
International Search Report and Written Opinion, PCT/US07/72396, dated Aug. 27, 2008, Applicant: Ardian, Inc., 9 pgs. |
International Search Report and Written Opinion, PCT/US07/84701, dated Aug. 21, 2008, Applicant: Ardian, Inc., 11 pgs. |
International Search Report and Written Opinion, PCT/US07/84705, dated Jul. 28, 2008, Applicant: Ardian, Inc., 12 pgs. |
International Search Report and Written Opinion, PCT/US07/84708, dated Aug. 11, 2008, Applicant: Ardian, Inc., 9 pgs. |
International Search Report, PCT/US02/0039, dated Sep. 11, 2002, Applicant: Advanced Neuromodulation Systems, Inc. |
International Search Report, PCT/US02/25712, dated Apr. 23, 2003, Applicant: Cyberonics, Inc. |
International Search Report, PCT/US03/08014, dated Sep. 23, 2003, Applicant: The General Hospital Corporation. |
International Search Report, PCT/US03/09764, dated Oct. 28, 2003, Applicant: CVRX, Inc. |
International Search Report, PCT/US04/38498, dated Feb. 18, 2005, Applicant: G & L Consulting, LLC, 4 pgs. |
Introduction to Autonomic Pharmacology, Chapter 3, Part 2 Autonomic Pharmacology, pp. 18-26, May 24, 2002. |
Isovue: Data Sheet. Regional Health Limited. 8 pgs. Mar. 11, 2003. |
Israili, Z.H., Clinical pharmacokinetics of angiotensin II (AT) receptor blockers in hypertension, Journal of Human Hypertension, 2000, Macmillan Publishers Ltd., vol. 14, pp. S73-S86. |
Janda, J., Impact of the electrical stimulation apparatus rebox on the course of ischemic renal damage in rats, British Library—The world's knowledge pp. 252-254 (translated and untranslated versions) 1996. |
Janssen, Ben J.A. et al., Effects of complete renal denervation and selective afferent renal denervation on the hypertension induced by intrarenal norepinephrine infusion in conscious rats, Jan. 4, 1989, Journal of Hypertension 1989, vol. 7, No. 6, Current Science Ltd, pp. 447-455. |
Jia, Jianping et al., Cold injury to nerves is not due to ischaemia alone, Brain. 121;pp. 989-1001. 1998. |
Jia, Jianping et al.., The pathogenesis of non-freezing cold nerve injury: Observations in the rat, Brain. 120; pp. 631-646. 1997. |
Jin, Yuanzhe et al., Pulmonary Vein Stenosis and Remodeling After Electrical Isolation for Treatment of Atrial Fibrillation: Short- and Medium-Term Follow-Up, PACE, vol. 27., Oct. 2004, pp. 1362-1370. |
Johansson, Bjorn, Electrical Membrane Breakdown, A Possible Mediator of the Actions of Electroconvulsive Therapy, Medical Hypotheses 1987, vol. 24, Longman Group UK Ltd 1987, pp. 313-324. |
Joles, J.A. et al., Causes and Consequences of Increased Sympathetic Activity in Renal Disease. Hypertension. 2004;43:699-706. |
Jorgensen, William A. et al., Electrochemical Therapy of Pelvic Pain: Effects of Pulsed Electromagnetic Fields (PEMF) on Tissue Trauma, Eur J Surg 1994, Suppl 574, vol. 160, 1994 Scandinavian University Press, pp. 83-86. |
Joshi, R. P. and K. H. Schoenbach, Mechanism for membrane electroporation irreversibility under high-intensity, ultrashort electrical pulse conditions, Nov. 11, 2002, Physical Review E 66, 2002, The American Physical Society 2002, pp. 052901-1-052901-4. |
Joshi, R. P. et al., Improved energy model for membrane electroporation in biological cells subjected to electrical pulses, Apr. 9, 2002, Physical Review E, vol. 65, 041920-1, 2002 The American Physical Society, 8 pages. |
Joshi, R. P. et al., Self-consistent simulations of electroporation dynamics in biological cells subjected to ultrashort electrical pulses, Jun. 21, 2001, Physical Review E, vol. 64, 011913, 2001 The American Physcial Society, pp. 1-10. |
Joye, James D.et al., In Vivo Study of Endovascular Cryotherapy for the Prevention of Restenosis, 4 pages, 2003. |
Kanduser, Masa et al., Effect of surfactant polyoxyethylene glycol (C12E8) on electroporation of cell line DC3F, Aug. 20, 2002, Colloids and Surfaces A: Physicochem. Eng. Aspects 214, 2003, Elsevier Science B.V. 2002, pp. 205-217. |
Kassab, S. et al., Renal denervation attenuates the sodium retention and hypertension associated with obesity, Hypertension, 1995, 25:893-897. |
Katholi, R.E. et al., Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension, Hypertension, 1982, 4 (suppl II): II-166-II-174. |
Katholi, R.E. et al., Role of the renal nerves in the pathogenesis of one-kidney renal hypertension in the rat, Hypertension, 1981, 3(4) 404-409. |
Katholi, R.E., Renal nerves and hypertension: an update, Fed Proc., 1985, 44:2846-2850. |
Katholi, Richard E., Renal nerves in the pathogenesis of hypertension in experimental animals and humans, Am. J. Physiol. vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
Kaye, D.M. et al., Functional and neurochemical evidence for partial cardiac sympathetic reinnervation after cardiac transplantation in humans, Circulation, 1993, vol. 88, pp. 1101-1109. |
Kelleher, Catherine L. et al., Characteristics of Hypertension in Young Adults with Autosomal Dominant Polycystic Kidney Disease Compared with the General U.S. Population, Jun. 9, 2004, American Journal of Hypertension 2004, pp. 1029-1034. |
King, Ronald W. P., Nerves in a Human Body Exposed to Low-Frequency Electromagnetic Fields, Jun. 7, 1999, IEEE Transactions on Biomedical Engineering, vol. 46, No. 12, Dec. 1999, IEEE 1999, pp. 1426-1431. |
Kinney, Brian M., M.D., High-Tech Healing—The evolution of therapeutic electromagnetic fields in plastic surgery, Plastic Surgery Products, Jun. 2004, pp. 32-36, 3 pages. |
Kirchheim, H. et al., Sympathetic modulation of renal hemodynamics, renin release and sodium excretion, Klin Wochenschr, 1989, 67:858-864. |
Klein, K. et al., Impaired autofeedback regulation of hypothalamic norepinephrine release in experimental uremia. J Am Soc Nephrol. 2005;16:2081-7. |
Knot, H. J. et al., Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure. The Journal of Physiology. 1998. 508; pp. 199-209. |
Kok, Lai Chow et al. Effect of Heating on Pulmonary Veins: How to Avoid Pulmonary Vein Stenosis. Journal of Cardiovascular Electrophysiology. vol. 14, No. 3, Mar. 2003. pp. 250-254. |
Kok, R. J. et al., Specific Delivery of Captopril to the Kidney with the Prodrug Captopril-Lysozyme, Aug. 16, 1998, Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 1, 1999 by The American Society for Pharmacology and Experimental Therapeutics, pp. 281-285. |
Kon, V. Neural Control of Renal Circulation, Miner Electrolyte Metab. 1989;15:33-43. |
Koomans, H.A., et al., Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524-37. |
Kopp, U. et al., Dietary sodium loading increases arterial pressure in afferent renal-denervated rats, Hypertension, 2003, 42:968-973. |
Kopp, U.C. et al., Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1561-72. |
Koyama, Shozo et al., Relative Contribution of Renal Nerve and Adrenal Gland to Renal Vascular Tone During Prolonged Canine Hemorrhagic Hypotension, Sep. 24, 1992, Circulatory Shock 1993, vol. 39, Wiley-Liss, Inc. 1993, pp. 269-274. |
Kozak, Lola Jean, Ph.D et al., National Hospital Discharge Survey: 2001 Annual Summary with Detailed Diagnosis and Procedure Data, Vital and Health Statistics, Serices 13 No. 156, Jun. 2004, CDC, 206 pages. |
Kumagai, K. et al. New Approach to Pulmonary Vein Isolation for Atrial Fibrillation Using a Multielectrode Basket Catheter. Circulation Journal. 2006;70:88-93. |
Lafayette, Richard A., M.D., How Does Knocking Out Angiotensin II Activity Reduce Renal Injury in Mice?, Jun. 14, 1999, Journal Club, American Journal of Kidney Diseases, vol. 35, No. 1, Jan. 2000, National Kidney Foundation, Inc. 2000, pp. 166-172. |
Lavie, Peretz, Ph.D. and Victor Hoffstein, M.D., Sleep Apnea Syndrome: A Possible Contributing Factor to Resistant Hypertension, Jun. 2001, Sleep 2001, vol. 24, No. 6, pp. 721-725. |
Le Noble, J.L. et al., Pharmacological evidence for rapid destruction of efferent renal nerves in rats by intrarenal infusion of 6-hydroxydopamine. J Hypertens Suppl. 1985;3:S137-40. |
Lee, Michael A. (editor). SPORTSMed. Connecticut State Medical Society Committee on the Medical Aspects of Sports. Fall/Winter 2005. 10 pgs. |
Lee, Raphael C. et al., Biophysical Injury Mechanisms in Electronic Shock Trauma, Annu. Rev. Biomed. Eng., 2000, vol. 2, Copyright © 2000 by Annual Reviews, pp. 477-509. |
Lee, Raphael C. et al., Clinical Sequelae Manifested in Electrical Shock Survivors, Presentation by the Electrical Trauma Research Program, The University of Chicago, 37 pages Dec. 24, 2004. |
Lee, Raphael C. et al., Membrane Biology and Biophysics, Chapter 25, Surgical Research, 2001 Academic Press, pp. 297-305. |
Lee, Raphael C., M.D., Sc.D. And Michael S. Kolodney, S.B., Electrical Injury Mechanisms: Electrical Breakdown of Cell Membranes, Oct. 1, 1986, Plastic and Reconstructive Surgery, Nov. 1987, vol. 80, No. 5, pp. 672-679. |
Lenoble, L.M. et al., Selective efferent chemical sympathectomy of rat kidneys. Am J Physiol. 1985;249:R496-501. |
Ligtenberg, Gerry M.D. et al., Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure, Apr. 29, 1999, New England Journal of Medicine 1999, vol. 340, No. 17, 1999 Massachusetts Medical Society, pp. 1321-1328. |
Lin, Vernon W. H. et al., High intensity magnetic stimulation over the lumbosacral spine evokes antinociception in rats, Apr. 16, 2002, Clinical Neurophysiology, vol. 113, 2002 Elsevier Science Ireland Ltd., pp. 1006-1012. |
Lipfert, Peter, M.D. et al., Tachyphylaxis to Local Anesthetics Does Not Result form Reduced Drug Effectiveness at the Nerve Itself, Aug. 3, 1988, Anesthesiology 1989, vol. 70, pp. 71-75. |
Lohmeier, Thomas E. and Drew A. Hildebrandt, Renal Nerves Promote Sodium Excretion in Angiotensin-Induced Hypertension, Oct. 20, 1997, Hypertension 1998, vol. 31, part 2, 1998 American Heart Association, Inc., pp. 429-434. |
Lohmeier, Thomas E. et al., Prolonged Activation of the Baroreflex Produces Sustained Hypotension, Harry Goldblatt Award, Nov. 26, 2003, Hypertension 2004, vol. 43, Part 2, 2004 American Heart Association, Inc., pp. 306-311. |
Lohmeier, Thomas E. et al., Renal Nerves Promote Sodium Excretion During Long-Term Increases in Salt Intake, Oct. 23, 1998, Hypertension 1999, vol. 33, part II, 1999 American Heart Association, Inc., pp. 487-492. |
Lohmeier, Thomas E. et al., Sustained influence of the renal nerves to attenuate sodium retention in angiotensin hypertension, Apr. 13, 2001, Am J Physiol Regulatory Integrative Comp Physiol, vol. 281, 2001 the American Physiological Society, pp. R434-R443. |
Lohmeier, Thomas E., et al., Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension, American Journal Physiol Regulatory Integrative Comp Physiol, vol. 279, 2000 the American Physiological Society, pp. R1437-R1448. |
Lohmeier, Thomas E., Interactions Between Angiotensin II and Baroreflexes in Long-Term Regulation of Renal Sympathetic Nerve Activity, Circulation Research, Jun. 27, 2003, American Heart Association, Inc.2003, pp. 1282-1284. |
Luff, S.E. et al., Two types of sympathetic axon innervating the juxtaglomerular arterioles of the rabbit and rat kidney differ structurally from those supplying other arteries, May 1, 1991, Journal of Neurocytology 1991, vol. 20, 1991 Chapman and Hall Ltd., pp. 781-795. |
Luippold, G. et al., Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats, Nephrol Dial Transplant (2004) 19:342-347. |
Lundborg, C. et al., Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I), Acta Anaesthesiol Scand 1999, vol. 43, pp. 667-678. |
Maeder, Micha, M.D. et al., Contrast Nephropathy: Review Focusing on Prevention, Jun. 22, 2004, Journal of the American College of Cardiology Nov. 2, 2004, vol. 44, No. 9, 2004 by the American College of Cardiology Foundation, pp. 1763-1771. |
Malpas, Simon C., What sets the long-term level of sympathetic nerve activity: is there a role for arterial baroreceptors?, Invited Review, Am J Physiol Regul Integr Comp Physiol 2004, vol. 286, 2004 the American Physiological Society, pp. R1-R12. |
Mancia, G., Grassi, G., Giannattasio, C., Seravalle, G., Sympathetic actrivation of pathogenesis of hypertension and progression of organ damage, Hypertension 1999, 34 (4 Pt 2): 724-728. |
Marenzi, Giancarlo, M.D. et al., The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration, New England Journal of Medicine, Oct. 2, 2003, vol. 349 (14), 2003 Massachusetts Medical Society, pp. 1333-1340. |
Market for infusion pumps grows with an aging population, NWL 97-01, The BBI Newsletter, vol. 20, No. 2, Feb. 1, 1997, American Health Consultants, Inc., pp. 6. |
Martin, Jason B. et al., Gene Transfer to Intact Mesenteric Arteries by Electroporation, Mar. 27, 2000, Journal of Vascular Research 2000, vol. 37, 2000 S. Karger AG, Basel, pp. 372-380. |
McCreery, Douglas B. et al., Charge Density and Charge Per Phase as Cofactors in Neural Injury Induced by Electrical Stimulation, IEEE Transactions on Biomedical Engineering, vol. 17, No. 10, Oct. 1990, pp. 996-1000. |
McCullough, Peter A., M.D., MPH et al., Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors and Relationship to Mortality, Apr. 14, 1997, Am J Med. 1997, vol. 103, 1997 Excerpta Medica, Inc., pp. 368-375. |
McMurray, John J.V., M.D. and Eileen O'Meara, M.D., Treatment of Heart Failure with Spironolactone—Trial and Tribulations, Aug. 5, 2004, New England Journal of Medicine, vol. 351, No. 6, 2004 Massachusetts Medical Society, pp. 526-528. |
McRobbie, D. and M.A. Foster, Thresholds for biological effects of time-varying magnetic fields, Dec. 16, 1983, Clin. Phys. Physiol. Meas. 1984, vol. 5, No. 2, 1984 The Institute of Physics, pp. 67-78. |
Medtronic Neurostimulation Systems, Expanding the Array of Pain Control Solutions, informational pamphlet, 1999 Medtronic, Inc., 6 pages. |
Medtronic, Spinal Cord Stimulation, Patient Management Guidelines for Clinicians, Medtronic, Inc. 1999, 115 pages. |
Medtronic, SynchroMed Infusion System—Clinical Reference Guide for Pain Therapy, Medtronic, Inc. 1998, 198 pages. |
Mehran, Roxana, Renal insufficiency and contrast nephropathy: The most common, least understood risk factor, Cardiovascular Research Foundation, Columbia University Medical Center, 2005, 86 slides. |
Mess, Sarah A., M.D. et al., Implantable Baclofen Pump as an Adjuvant in Treatment of Pressure Sores, Mar. 1, 2003, Annals of Plastic Surgery, vol. 51, No. 5, Nov. 2003, Lippincott Williams & Wilkins 2003, pp. 465-467. |
Micro ETS Hyperhidrosis USA Hyperhidrosis USA. 2 pgs. <URL: http://www.hyperhidrosis-usa.com/Index.html>. Nov. 6, 2006. |
Mihran, Richard T. et al., Temporally-Specific Modification of Myelinated Axon Excitability in Vitro Following a Single Ultrasound Pulse, Sep. 25, 1989, Ultrasound in Med. & Biol. 1990, vol. 16, No. 3, pp. 297-309. |
Miklav{hacek over (c)}i{hacek over (c)}, D. et al, A Validated Model of in Vivo Electric Field Distribution in Tissues for Electrochemotherapy and for DNA Electrotransfer for Gene Therapy, Biochimica et Biophysica Acta, 1523, 2000, pp. 73-83, <http:www.elsevier.com/locate/bba>. |
Mitchell, G. A. G., The Nerve Supply of the Kidneys, Aug. 20, 1949, Acta Anatomica, vol. X, Fasc. ½, 1950, pp. 1-37. |
Morrisey, D.M. et al., Sympathectomy in the treatment of hypertension: Review of 122 cases, Lancet. 1953;1:403-408. |
Moss, Nicholas G., Renal function and renal afferent and efferent nerve activity, Am. J. Physiol. 1982, vol. 243, 1982 the American Physiological Society, pp. F425-F433. |
Munglani, Rajesh, The longer term effect of pulsed radiofrequency for neuropathic pain, Jun. 8, 1998, Pain 80, 1999, International Association for the Study of Pain 1999, Published by Elsevier Science B.V., pp. 437-439. |
Naropin (ropivacaine HCl) Injection, RX only Description, AstraZeneca 2001, 3 pages. |
National High Blood Pressure Education Program, 1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension, presentation, 13 pages. |
National Kidney Foundation, Are You at Increased Risk for Chronic Kidney Disease?, 2002 National Kidney Foundation, Inc., 14 pages. |
Nelson, L. et al., Neurogenic Control of Renal Function in Response to Graded Nonhypotensive Hemorrahage in Conscious Dogs, Sep. 13, 1992, Am J. Physiol. 264, 1993, American Physiological Society 1993, pp. R661-R667. |
Nikolsky, Eugenia, M.D. et al., Radiocontrast Nephropathy: Identifying the High-Risk Patient and the Implications of Exacerbating Renal Function, Rev Cardiovasc Med. 2003, vol. 4, Supp. 1, 2003 MedReviews, LLC, pp. S7-S14. |
Non-Final Office Action; U.S. Appl. No. 10/408,665; dated Mar. 21, 2006, 14 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/129,765; dated May 18, 2007, 10 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/129,765; dated Sep. 10, 2007, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/129,765; dated Oct. 6, 2006, 30 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/133,925; dated Oct. 8, 2008, 41 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,173; dated Apr. 5, 2007, 33 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,173; dated Sep. 10, 2007, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Oct. 29, 2009, 8 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Apr. 5, 2007, 33 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Sep. 10, 2007, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/144,298; dated Dec. 29, 2008, 7 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/145,122; dated Apr. 11, 2007, 33 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/145,122; dated Sep. 10, 2007, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/189,563; dated May 28, 2009, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/233,814; dated Jun. 17, 2008, 12 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/252,462; dated Feb. 22, 2010, 6 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/266,993; dated Jul. 8, 2009, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/266,993; dated Dec. 30, 2008, 7 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/363,867; dated Sep. 25, 2008, 10 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/368,553; dated May 18, 2010, 4 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/368,553; dated Oct. 7, 2009, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/368,809; dated Dec. 3, 2009, 4 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/368,949; dated Jun. 11, 2010, 6 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/368,971; dated Aug. 24, 2010, 9 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Jun. 12, 2008, 41 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Jul. 2, 2009, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/451,728; dated Dec. 28, 2009, 7 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/504,117; dated Mar. 31, 2009, 10 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/599,649; dated Mar. 30, 2009, 10 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/599,649; dated Jun. 23, 2008, 9 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/599,723; dated Jun. 26, 2009, 17 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/599,723; dated Oct. 15, 2010, 16 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/599,882; dated Jul. 6, 2009, 13 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/688,178; dated Jun. 28, 2010, 5 pgs. |
Non-Final Office Action; U.S. Appl. No. 11/840,142; dated Apr. 3, 2009, 13 pgs. |
Non-Final Office Action; U.S. Appl. No. 12/567,521; dated Sep. 3, 2010, 9 pgs. |
Non-Final Office Action; U.S. Appl. No. 12/616,708; dated Sep. 16, 2010, 10 pgs. |
Non-Final Office Action; U.S. Appl. No. 12/725,375; dated Oct. 12, 2010, 14 pgs. |
Nozawa, T.et al., Effects of Long Term Renal Sympathetic Denervation on Heart Failure After Myocardial Infarction in Rats, Sep. 22, 2001, Heart Vessels, 2002, 16, Springer-Verlag 2002, pp. 51-56. |
O'Hagan, K.P. et al., Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension, Am J Hypertens., 1990, 3:62-64. |
Onesti, G. et al., Blood pressure regulation in end-stage renal disease and anephric man, Circ Res Suppl., 1975, 36 & 37: 145-152. |
Osborn, et al., Effect of renal nerve stimulation on renal blood flow autoregulation and antinatriuresis during reductions in renal perfusion pressure, in Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. (Abstract). |
Packer, Douglas L. et al., Clinical Presentation, Investigation, and Management of Pulmonary Vein Stenosis Complication Ablation for Atrial Fibrillation, Circulation: Journal of the American Heart Association. Feb. 8, 2005. pp. 546-554. |
Page, I.H. et al., The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension. J Clin Invest. 1935;14:27-30. |
Page, I.H., et al., The Effect of Renal Efficiencyof Lowering Arterial Blood Pressure in Cases of Essential Nephritis, Hospital of the Rockefeller Institue, Jul. 12, 1934, 7 pgs. |
Palmer, Biff, F., M.D., Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System, Aug. 5, 2004, The New England Journal of Medicine 2004, vol. 351;6, 2004 Massachusetts Medical Society, pp. 585-592. |
Pappone, Carlo et al., [2005][P2-70] Safety Report of Circumferential Pulmonary Vein Ablation. A 9-Year Single-Center Experience on 6,442 Patients with Atrial Fibrillation, Abstract only. 1 page, May 2005. |
Pappone, Carlo et al., [2004][759] Pulmonary Vein Denervation Benefits Paroxysmal Atrial Fibrillation Patients after Circumferential Ablation, Abstract only. 1 page, Jan. 5, 2004. |
Pappone, Carol and Santinelli, Vincenzo. Multielectrode basket catheter: A new tool for curing atrial fibrillation? Heart Rhythm, vol. 3, Issue 4, pp. 385-386. Apr. 2006. |
Peacock, J.M. and R. Orchardson, Action potential conduction block of nerves in vitro by potassium citrate, potassium tartrate and potassium oxalate, May 6, 1998, Journal of Clinical Periodontology, Munksgaard 1999, vol. 26, pp. 33-37. |
Petersson, M. et al., Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26:906-13. |
Pettersson, A. et al., Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure, Nov. 25, 1988, Acta Physiol Scand 1989, 135, pp. 487-492. |
PHCL 762 Pharmacology of the Autonomic Nervous System, Chapter 2 and 6.8 in Mosby, http://www.kumc.edu/research/medicine/pharmacology/CAI/phcl762.html, last accessed Aug. 24, 2004, 14 pgs. |
Pitt, B. et al., Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study, Circulation, 2003, vol. 108, pp. 1831-1838. |
Pliquett, U., Joule heating during solid tissue electroporation, Oct. 22, 2002, Med. Biol. Eng. Comput., 2003, vol. 41, pp. 215-219. |
Podhajsky R.J. et al, The Histologic Effects of Pulsed and Continuous Radiofrequency Lesions at 42 C to Rat Dorsal Root Ganglion and Sciatic Nerve, Spine, vol. 30, No. 9, 2005, Lippincott Williams & Wilkins Inc., pp. 1008-1013. |
Pope, Jill. Fixing a Hole: Treating Injury by Repairing Cells. The New York Academy of Sciences. Jul. 6, 2006. 6 pgs. |
Popovic, Jennifer R. and Margaret J. Hall, 1999 National Hospital Discharge Survey, Apr. 24, 2001, Advance Data, No. 319, CDC, pp. 1-17 & 20. |
Practice Guidelines Writing Committee and ESH/ESC Hypertension Guidelines Committee, Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines, Published in Journal of Hypertension 2003, vol. 21, No. 10: 1011-1053, European Society of Hypertension 2003, pp. 1779-1786. |
Programmable Infusion System, Pumps and Pump Selection, Medtronic Pain Therapies, Medtronic, Inc. Sep. 5, 2001, 2 pgs. |
Pucihar, Gorazd et al., The influence of medium conductivity on electropermeabilization and survival of cells in vitro, May 31, 2001, Bioelectrochemistry, vol. 54, 2001, Elsevier Science B.V. 2001, pp. 107-115. |
Pulmonary Concepts in Critical Care Breath Sounds, http://rnbob.tripod.com/breath.htm, last accessed Aug. 23, 2004, 5 pages. |
Pulmonary Function Testing, http://jan.ucc.nau.edu/˜daa/lecture/pft.htm, last accessed Aug. 23, 2004, 8 pages. |
Purerfellner, Helmut and Martinek, Martin. Pulmonary vein stenosis following catheter ablation of atrial fibrillation. Current Opinion in Cardiology. 20; pp. 484-490. 2005. |
Purerfellner, Helmut et al., Pulmonary Vein Stenosis by Ostial Irrigated-Tip Ablation: Incidence, Time Course, and Prediction, Journal of Cardiovascular Electrophysiology. vol. 14, No. 2, Feb. 2003. pp. 158-164. |
Raji, A. R. M. and R. E. M. Bowden, Effects of High-Peak Pulsed Electromagnetic Field on the Degeneration and Regeneration of the Common Peroneal Nerve in Rats, The Journal of Bone and Joint Surgery Aug. 1983, vol. 65-B, No. 4, 1983 British Editorial Society of Bone and Joint Surgery, pp. 478-492. |
Ram, C. Venkata S., M.D., Understanding refractory hypertension, May 15, 2004, Patient Care May 2004, vol. 38, pp. 12-16, 7 pages from http://www.patientcareonline.com/patcare/content/printContentPopup.jsp?id=108324. |
Ravalia, A. et al., Tachyphylaxis and epidural anaesthesia, Edgware General Hospital, Correspondence, p. 529, Jun. 1989. |
Renal Parenchymal Disease, Ch. 26, 5th Edition Heart Disease, A Textbook of Cardiovascular Medicine vol. 2, Edited by Eugene Braunwald, WB Saunders Company, pp. 824-825 1997. |
Ribstein, Jean and Michael H. Humphreys, Renal nerves and cation excretion after acute reduction in functioning renal mass in the rat, Sep. 22, 1983, Am. J. Physiol., vol. 246, 1984 the American Physiological Society, pp. F260-F265. |
Richebe, Philippe, M.D. et al., Immediate Early Genes after Pulsed Radiofrequency Treatment: Neurobiology in Need of Clinical Trials, Oct. 13, 2004, Anesthesiology Jan. 2005, vol. 102, No. 1, 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1-3. |
Rihal, Charanjit S. et al., Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention, Mar. 6, 2002, Circulation May 14, 2002, vol. 10, 2002 American Heart Association, Inc., pp. 2259-2264. |
Rosen, S.M. et al., Relationship of Vascular Reactivity to Plasma Renin Concentration in Patients with Terminal Renal Failure, Proc. Dialysis Transplant Forum 1974, pp. 45-47. |
Roth, Bradley J. and Peter J. Basser, A Model of the Stimulation of a Nerve Fiber by Electromagnetic Induction, IEEE Transactions on Biomedical Engineering, vol. 37, No. 6, Jun. 1990, pp. 588-597. |
Rudin, Asa, M.D. et al., Postoperative Epidural or Intravenous Analgesia after Major Abdominal or Thoraco-Abdominal Surgery, The Journal of the American Society of Anesthesiologists, Inc., Anesthesiology 2001, vol. 95, A-970, 1 page. |
Rudnick, Michael R. et al., Contrast-induced nephropathy: How it develops, how to prevent it, Cleveland Clinic Journal of Medicine Jan. 2006, vol. 73, No. 1, pp. 75-87. |
Rump, L.C., The Role of Sympathetic Nervous Activity in Chronic Renal Failure, J Clinical Basic Cardiology 2001, vol. 4, pp. 179-182. |
Ruohonen, Jarmo et al., Modeling Peripheral Nerve Stimulation Using Magnetic Fields, Journal of the Peripheral Nervous System, vol. 2, No. 1, 1997, Woodland Publications 1997, pp. 17-29. |
Saad, Eduardo B. et al., Pulmonary Vein Stenosis After Radiofrequency Ablation of Atrial Fibrillation: Functional Characterization, Evolution, and Influence of the Ablation Strategy, Circulation. 108; pp. 3102-3107. 2003. |
Sabbah, Hani N., Animal Models for Heart Failure and Device Development, Henry Ford Health System. 24 slides, Oct. 17, 2005. |
Schauerte, P et al., Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system, Journal of Cardiovascular Electrophysiology. 12(5). May 2001. Abstract only. 2 pgs. |
Schauerte, P et al., Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation, Circulation. 102(22). Nov. 28, 2000. Abstract only. 2 pgs. |
Schauerte, P et al., Transvenous parasympathetic nerve stimulation in the inferior vena cava and atrioventricular conduction, Journal of Cardiovascular Electrophysiology. 11(1). Jan. 2000. Abstract only. 2 pgs. |
Scheiner, Avram, Ph.D., The design, development and implementation of electrodes used for functional electrial stimulation, Thesis paper, Case Western Reserve University, May 1992, 220 pages. |
Scherlag, BJ and Po, S., The intrinsic cardiac nervous system and atrial fibrillation, Current Opinion in Cardiology. 21(1):51-54, Jan. 2006. Abstract only. 2 pgs. |
Schlaich, M.P. et al., Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-5. |
Schlaich, M.P. et al., Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation, Hypertension, 2004, 43:169-175. |
Schmitt, Joseph et al., Intravascular Optical Coherence Tomography—Opening a Window into Coronary Artery Disease, LightLab Imaging, Inc. Business Briefing: European Cardiology 2005. |
Schoenbach, Karl H. et al, Intracellular Effect of Ultrashort Electrical Pulses, Dec. 26, 2000, Bioelectromagnetics, vol. 22, 2001, Wiley-Liss, Inc. 2001, pp. 440-448. |
Schrier, Robert et al., Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycistic Kidney Disease, Mar. 23, 2002, Journal of the American Society of Nephrology, American Society of Nephrology 2002, pp. 1733-1739. |
Scremin, Oscar U., M.D., Ph.D. and Daniel P. Holschneider, M.D., 31 & 32.. An Implantable Bolus Infusion Pump for the Neurosciences, FFP, Apr. 2005, 3 pages. |
Sensorcaine—MPF Spinal Injection, informational document, AstraZeneca 2001, 2 pgs. |
Shah, D.C., Haissaguerre, M., Jais, P., Catheter ablation of pulmonary vein foci for atrial fibrillation: pulmonary vein foci ablation for atrial firbrillation, Thorac Cardiovasc Surg, 1999, 47 (suppl. 3): 352-356. |
Shannon, J.L. et al., Studies on the innervation of human renal allografts, J Pathol. 1998, vol. 186, pp. 109-115. |
Shlipak, M.G. et al., The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514-7. |
Shupak, Naomi M., Therapeutic Uses of Pulsed Magnetic-Field Exposure: A Review, Radio Science Bulletin Dec. 2003, No. 307, pp. 9-32. |
Shu-Qing, Liu et al., Old spinal cord injury treated by pulsed electric stimulation, General Hospital of Beijing Command, Beijing, Dec. 6, 1990, 5 pages (full article in Chinese; abstract on last page). |
Siegel, RJ et al., Clinical demonstration that catheter-delivered ultrasound energy reverses arterial vasoconstriction, Journal of the American College of Cardiology. 1992. 20; 732-735. Summary only. 2 pgs. |
Simpson, B. et al., Implantable spinal infusion devices for chronic pain and spasticity: an accelerated systematic review, ASERNIP-S Report No. 42, Adelaide, South Australia, ASERNIP-S, May 2003, 56 pages. |
Sisken, B.F. et al., 229.17 Influence of Non-Thermal Pulsed Radiofrequency Fields (PRF) on Neurite Outgrowth, Society for Neuroscience, vol. 21, 1995, 2 pages. |
Skeie, B. et al., Effect of chronic bupivacaine infusion on seizure threshold to bupivacaine, Dec. 28, 1986, Acta Anaesthesiol Scand 1987, vol. 31, pp. 423-425. |
Skopec, M., A Primer on Medical Device Interactions with Magnetic Resonance Imaging Systems, Feb. 4, 1997, CDRH Magnetic Resonance Working Group, U.S. Department of Heatlh and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Updated May 23, 1997, 17 pages, http://www.fda.gov/cdrh/ode/primerf6.html, (last accessed Jan. 23, 2006. |
Slappendel, Robert et al., The efficacy of radiofrequency lesioning of the cervical spinal dorsal root ganglion in a double blinded randomized study, Jun. 26, 1997, Pain 73, 1997 International Association for the Study of Pain, Elsevier Science B.V., pp. 159-163. |
Sluijter, M.D., Ph.D., Pulsed Radiofrequency, May 17, 2005, Anesthesiology Dec. 2005, vol. 103, No. 6, 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc., pp. 1313-1314. |
Sluijter, M.D., Ph.D., Radiofrequency Part 1: The Lumbosacral Region, Chapter 1 Mechanisms of Chronic Pain and part of Chapter 2 Spinal Pain, 2001 FlivoPress SA, Meggen (LU), Switzerland, pp. 1-26. |
Sluijter, M.D., Ph.D., Radiofrequency Part 2: Thoracic and Cervical Region, Headache and Facial Pain, various pages from, FlivoPress SA, Meggen (LU), Switzerland, 13 pages 2002. |
Sluijter, M.D., Ph.D., The Role of Radiofrequency in Failed Back Surgery Patients, Current Review of Pain 2000, vol. 4, 2000 by Current Science Inc., pp. 49-53. |
Smithwick, R.H. et al., Hypertension and associated cardiovascular disease: comparison of male and female mortality rates and their influence on selection of therapy, JAMA, 1956, 160:1023-1033. |
Smithwick, R.H. et al., Splanchnicectomy for essential hypertension, Journal Am Med Assn, 1953;152:1501-1504. |
Smithwick, R.H., Surgical treatment of hypertension, Am J Med 1948, 4:744-759. |
Sobotka, Paul A., Treatment Strategies for Fluid Overload, CHF Patients, CHF Solutions. Transcatheter Cardiovascular Therapeutics 2005. 20 slides. |
Solis-Herruzo, J.A. et al., Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome, Journal of Hepatology, 1987; 5: 167-173. |
Souza, D.R.B. et al., Chronic experimental myocardial infarction produces antinatriuresis by a renal nerve-dependent mechanism, Oct. 14, 2003, Brazilian Journal of Medical and Biological Research 2004, vol. 37, pp. 285-293. |
Standl, Thomas, M.D., et al., Patient-controlled epidural analgesia reduces analgesic requirements compared to continuous epidural infusion after major abdominal surgery, Aug. 29, 2002, Canada Journal of Anesthesia 2003, vol. 50 (3), pp. 258-264. |
Steffen, W. et al., Catheter-delivered high intensity, low frequency ultrasound induces vasodilation in vivo, European Heart Journal. 1994. 15; pp. 369-376. |
Steg, PG et al., Pulsed ultraviolet laser irradiation produces endothelium-independent relaxation of vascular smooth muscle, Circulation: Journal of the American Heart Association. 1989. pp. 189-197. |
Stone, Gregg W., M.D. et al., Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy, JAMA Nov. 5, 2003, vol. 290, No. 17, 2003 American Medical Association, pp. 2284-2291. |
Strojek, K. et al., Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001 ;12:602-5. |
Summary, Critical Reviews in Biomedical Engineering, vol. 17, Issue 5, 1989, pp. 515-529. |
Sung, Duk Hyun, M.D. et al., Phenol Block of Peripheral Nerve Conduction: Titrating for Optimum Effect, Jun. 27, 2000, Arch. Phys. Med. Rehabil. vol. 82, May 2001, pp. 671-676. |
Taka, Tomomi et al., Impaired Flow-Mediated Vasodilation in vivo and Reduced Shear-Induced Platelet Reactivity in vitro in Response to Nitric Oxide in Prothrombotic, Stroke-Prone Spontaneously Hypertensive Rats, Pathophysiology of Haemostasis and Thrombosis. Dec. 23, 2002. pp. 184-189. |
Taler, Sandra J. et al., Resistant Hypertension, Comparing Hemodynamic Management to Specialist Care, Mar. 12, 2002, Hypertension 2002, vol. 39, 2002 American Heart Association, Inc., pp. 982-988. |
Tamborero, David et al., Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs. the Circumferential Pulmonary Veins Ablation, Journal of Intervocational Cardiac Electrophysiology. 14; pp. 41-25. 2005. |
Tay, Victoria KM, et al., Computed tomography fluoroscopy-guided chemical lumbar sympathectomy: Simple, safe and effective, Oct. 31, 2001, Diagnostic Radiology, Australasian Radiology 2002, vol. 46, pp. 163-166. |
Terashima, Mitsuyasu et al. Feasibility and Safety of a Novel CryoPlasty™ System. Poster. 1 page, Mar. 15, 2002. |
Thatipelli et al., CT Angiography of Renal Artery Anatomy for Evaluating Embolic Protection Devices, Journal of Vascular and Interventional Radiology, Jul. 2007, pp. 842-846. |
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT Research Group, JAMA, 2002, vol. 288, pp. 2981-2997. |
Thomas, John R. and Oakley, E. Howard N. Chapter 15: Nonfreezing Cold Injury Medical Aspects of Harsh Environments, vol. 1. pp. 467-490, 2001. |
Thompson, Gregory W., et al., Bradycardia Induced by Intravascular Versus Direct Stimulation of the Vagus Nerve, Aug. 24, 1997, The Society of Thoracic Surgeons 1998, pp. 637-642. |
Thrasher, Terry N., Unloading arterial baroreceptors causes neurogenic hypertension, Dec. 4, 2001, Am J. Physiol Regulatory Integrative Comp Physiol, vol. 282, 2002 the American Physiological Society, pp. R1044-R1053. |
Tokuno, Hajime A. et al., Local anesthetic effects of cocaethylene and isopropylcocaine on rat peripheral nerves, Oct. 7, 2003, Brain Research 996, 2004, Elsevier B.V. 2003, pp. 159-167. |
Trapani, Angelo J. et al., Neurohumoral interactions in conscious dehydrated rabbit, Am. J. Physiol. 254, 1988, the American Physiological Society 1988, pp. R338-R347. |
Trock, David H. et al., The Effect of Pulsed Electromagnetic Fields in the Treatment of Osteoarthritis of the Knee and Cervical Spine. Report of Randomized, Double Blind, Placebo Controlled Trials, Mar. 22, 1994, The Journal of Rheumatology 1994, vol. 21, pp. 1903-1911. |
Troiano, Gregory C. et al., The Reduction in Electroporation Voltages by the Addition of a Surfactant to Planar Lipid Bilayers, May 12, 1998, Biophysical Journal, vol. 75, Aug. 1998, the Biophysical Society 1998, pp. 880-888. |
Trumble, Dennis R. and James A. MaGovern, Comparison of Dog and Pig Models for Testing Substernal Cardiac Compression Devices, Nov. 2003, ASAIO Journal 2004, pp. 188-192. |
Tsai, E., Intrathecal drug delivery for pain indications, technique, results, Pain Lecture presentation, Jun. 8, 2001, 31 pages. |
Uematsu, Toshihiko, M.D., Ph.D., F.I.C.A. et al., Extrinsic Innervation of the Canine Superior Vena Cava, Pulmonary, Portal and Renal Veins, Angiology—Journal of Vascular Diseases, Aug. 1984, pp. 486-493. |
United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
Upadhyay, Pramod, Electroporation of the skin to deliver antigen by using a piezo ceramic gas igniter, Jan. 27, 2001, International Journal of Pharmaceutics, vol. 217, 2001 Elsevier Science B.V., pp. 249-253. |
Valente, John F. et al., Laparoscopic renal denervation for intractable ADPKD-related pain, Aug. 24, 2000, Nephrol Dial Transplant 2001, vol. 16, European Renal Association—European Dialysis and Transplant Association, p. 160. |
Van Antwerp, Bill and Poonam Gulati, Protein Delivery from Mechanical Devices Challenges and Opportunities, Medtronic presentation, 19 pages, Jul. 2003. |
Velazquez, Eric J., An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: The VALIANT registry, Aug. 5, 2004, European Heart Journal vol. 25, 2004 Elsevier, pp. 1911-1919. |
Velez-Roa, Sonia, M.D. et al., Peripheral Sympathetic Control During Dobutamine Infusion: Effects of Aging and Heart Failure, Jul. 7, 2003, Journal of the American College of Cardiology, vol. 42, No. 9, 2003, American College of Cardiology Foundation 2003, pp. 1605-1610. |
Villarreal, Daniel et al., Effects of renal denervation on postprandial sodium excretion in experimental heart failure, Oct. 29, 1993, Am J Physiol 266, 1994, pp. R1599-R1604. |
Villarreal, Daniel et al., Neurohumoral modulators and sodium balance in experimental heart failure, Nov. 6, 1992, Am. J. Physiol, vol. 264, 1993, pp. H1187-H1193. |
Vonend, O. et al., Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709-17. |
Wagner, C.D. et al., Very low frequency oscillations in arterial blood pressure after autonomic blockade in conscious dogs, Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
Wald, Jan D., Ph.D, et al., Cardiology Update: 2003, Sep. 11, 2003, AG Edwards 2003, 120 pages. |
Wang, Xi et al., Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure, Jul. 2004, Am J Physiol Heart Circ Physiol vol. 287, 2004 the American Physiological Society, pp. H118-H125. |
Weaver, James C., Chapter 1 Electroporation Theory, Concepts and Mechanisms, Methods in Molecular Biology, vol. 55, Plant Cell Electroporation and Electrofusion Protocols, Edited by J.A. Nickoloff, Humana Press Inc., pp. 3-28, 1995. |
Weaver, James C., Electroporation: A General Phenomenon for Manipulating Cells and Tissues, Oct. 22, 1992, Journal of Cellular Biochemistry, vol. 51, 1993 Wiley-Liss, Inc., pp. 426-435. |
Weiner, Richard L., M.D., Peripheral nerve neurostimulation, Neurosurg. Clin. N. Am. vol. 14, 2003, Elsevier, Inc. 2003, pp. 401-408. |
Weisbord, Steven D., M.D. and Paul M. Palevsky, M.D., Radiocontrast-Induced Acute Renal Failure, Jul. 10, 2004, Journal of Intensive Care Medicine 2005, vol. 20 (2), 2005 Sage Publications, pp. 63-75. |
Whitelaw, G.P., Kinsey, D., Smithwick, R.H., Factors influencing the choice of treatment in essential hypertension: surgical, medical, or a combination of both, Am J Surg, 1964, 107:220-231. |
Wilson, D.H. et al., The Effects of Pulsed Electromagnetic Energy on Peripheral Nerve Regeneration, Annals New York Academy of Sciences, Oct. 1974, pp. 575-585. |
Wolinsky, Harvey, M.D. PhD and Swan N. Thung, M.D., Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery, Aug. 30, 1989, JACC 1990, vol. 15, 1990 by the American College of Cardiology, pp. 475-481. |
Wyss, J. Michael et al., Neuronal control of the kidney: Contribution to hypertension, Apr. 8, 1991, Can. J. Physiol. Pharmacol. 1992;70: 759-770. |
Yamaguchi, Jun-ichi, M.D. et al., Prognostic Significance of Serum Creatinine Concentration for In-Hospital Mortality in Patients with Acute Myocardial Infarction Who Underwent Successful Primary Percutaneous Coronary Intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry), Feb. 24, 2004, The American Journal of Cardiology vol. 93, Jun. 15, 2004, 2004 by Excerpta Medica, Inc., pp. 1526-1528. |
Ye, Richard D., M.D., Ph.D., Pharmacology of the Peripheral Nervous System, E-425 MSB, 6 pages, Jan. 2000. |
Ye, S. et al., A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11:723-8. |
Ye, Shaohua et al., Renal Injury Caused by Intrarenal Injection of Pheno Increases Afferent and Efferent Renal Sympathetic Nerve Activity, Mar. 12, 2002, American Journal of Hypertension, Aug. 2002, vol. 15, No. 8, 2002 the American Journal of Hypertension, Ltd. Published by Elsevier Science Inc., pp. 717-724. |
Yong-Quan, Dong et al., The therapeutic effect of pulsed electric field on experimental spinal cord injury, Beijing Army General Hospital of People's Liberation Army, Beijing, 5 pages (full article in Chinese; abstract on last page) Mar. 30, 1992. |
Young, James B., M.D., FACC, Management of Chronic Heart Failure: What Do Recent Clinical Trials Teach Us?, Reviews in Cardiovascular Medicine, vol. 5, Suppl. 1, 2004, MedReviews, LLC 2004, pp. S3-S9. |
Yu, Wen-Chung et al. Acquired Pulmonary Vein Stenosis after Radiofrequency Catheter Ablation of Paroxysmal Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. vol. 12, No. 8. Aug. 2001. pp. 887-892. |
Zanchetti, A. et al., Neural Control of the Kidney—Are There Reno-Renal Reflexes?, Clin. and Exper. Hyper. Theory and Practice, A6 (1&2), 1984, Marcel Dekker, Inc. 1984, pp. 275-286. |
Zanchetti, A. et al., Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines, Journal of Hypertension, vol. 21, No. 10, 2003, pp. 1779-1786. |
Zanchetti, A.S., Neural regulation of renin release: Experimental evidence and clinical implications in arterial hypertension, Circulation, 1977, 56(5) 691-698. |
Zimmermann, Ulrich, Electrical Breakdown, Electropermeabilization and Electrofusion, Rev. Physiol. Biochem. Pharmacol., vol. 105, Springer-Verlag 1986, pp. 175-256. |
Zoccali, C. et al., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-9. |
Zucker, Irving H. et al., The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide, Progress in Biophysics & Molecular Biology, vol. 84, 2004, Elsevier Ltd. 2003, pp. 217-232. |
Zundert, Jan Van, M.D. FIPP and Alex Cahana, M.D. DAAPM, Pulsed Radiofrequency in Chronic Pain Management: Looking for the Best Use of Electrical Current, Pain Practice 2005, vol. 5, Issue 2, 2005 World Institute of Pain, pp. 74-76. |
Miller, Reed, “Finding a Future for Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article # 01141006003, Oct. 6, 2014, 4 pages. |
Papademetriou, Vasilios, “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt Is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450. |
Papademetriou, Vasilios et al., “Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension. 2014; 64: 565-572. |
Doumas, Michael et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
Gonschior, P., Comparison of Local Intravascular Drug-Delivery Catheter Systems, Am. Heart J., Dec. 1995, 130:6, 1174-81. |
European Search Report for Application No. 10159584.1, dated Jun. 10, 2013, 9 pages. |
Pieper et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping.” Journal of Applied Physiology, 1991, vol. 71, No. 4, pp. 1529-1539. |
Remo, Benjamin F. et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy.” Heart Rhythm, 2014, 11(4), 541-6. |
U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pages. |
Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs. |
Number | Date | Country | |
---|---|---|---|
20150005676 A1 | Jan 2015 | US |
Number | Date | Country | |
---|---|---|---|
60816999 | Jun 2006 | US | |
60370190 | Apr 2002 | US | |
60415575 | Oct 2002 | US | |
60442970 | Jan 2003 | US | |
60616254 | Oct 2004 | US | |
60624793 | Nov 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13765487 | Feb 2013 | US |
Child | 14298121 | US | |
Parent | 12700524 | Feb 2010 | US |
Child | 13765487 | US | |
Parent | 11840142 | Aug 2007 | US |
Child | 12700524 | US | |
Parent | 11504117 | Aug 2006 | US |
Child | 11840142 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10408665 | Apr 2003 | US |
Child | 11504117 | US | |
Parent | 11189563 | Jul 2005 | US |
Child | 10408665 | US | |
Parent | 11129765 | May 2005 | US |
Child | 11189563 | US |